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CHAPTER 1: Introduction 
1.1 Breast Cancer: A Review  
While billions of dollars have been designated to cancer research, care, and 
education, the number of people developing this disease is still on the rise. Early 
detection and better treatments have increased survival for almost all types, but cancer 
is still the second leading cause of death in the United States, after heart disease. More 
effective treatment options need to be developed to increase survival rates for patients. 
The focus of this dissertation is a combination targeted therapy for triple negative breast 
cancer (TNBC) and the molecular mechanisms of the therapy.  
Breast cancer is the second leading cause of cancer related deaths and remains 
the most diagnosed among American women. It is estimated that in 2013 there were 
232,340 new cases and 39,620 deaths attributed to breast cancer in women, 
accounting for 14% of all female cancer incidence. The lifetime risk for a woman to 
develop breast cancer is one in eight, with the highest risk of development occurring at 
70 years or older (ACS, 2013). 
 Public awareness of the disease has been greatly increased by organizations 
such as Susan G Komen for the Cure, and campaigns such as “October is Breast 
Cancer Awareness Month” and the Pink Ribbon. Many women are routinely getting 
mammograms and checking for early detection, but even early detection has not greatly 
reduced breast cancer related mortality. Public awareness and knowledge about breast 
cancer has increased to the level where women are actively advocating for more 
effective treatments and better survival rates. The influx of research dollars from 
fundraising organizations and campaigns has led to many advances in the field but 
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much is still unknown about the etiology of breast cancer and the most effective 
treatments. 
 Breast cancer is a very heterogeneous disease and can be characterized into 
four molecular subtypes based on gene expression profiling: Luminal A, Luminal B, 
HER2+, and Basal (Goldhirsch et al., 2011; Schnitt, 2010). Table 1 describes these 
subtypes and the current therapeutic options. The guidelines are meant to serve as a 
reference for physicians to treat the individual patient based on a variety of other clinical 
and pathological factors. These include patient age, overall health, and the stage and 
grade of the tumor (Schnitt, 2010). Age is often a factor in relation to menopause status. 
Hormone therapy is often reserved for post-menopausal women or as a last option for 
pre-menopausal women as the side effects from hormone ablation are greater in the 
pre-menopausal population (ACS, 2013). The subtypes have different incidence and 
mortality rates. Luminal A cancers comprise 40% of all diagnosed breast cancers and 
according to data from the Carolina Breast Study, have an 84% survival rate.  Luminal B 
cancers are less prevalent at 20% but have a slightly better prognosis with an 87% 
survival rate. HER2+ cancers have a good molecular target and drug, trastuzumab, but 
their survival rate is only 52%, and the subtype comprises 10-15% of all breast cancers. 
The basal-like subtype is predominantly TNBC but not all basal cancers are TNBC and 
not all TNBC is basal-like. Basal-like cancers had a prognosis of 75% in the Carolina 
cohort. It also comprises about 20% of breast cancers (Carey et al., 2006). Basal-like 
tumors, particularly TNBC, are highly aggressive and have a poor prognosis compared 
to the most common luminal cancers so we need to find a better treatment option that 
has low toxicity and combats developed resistance for TNBC patients.  
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1.1.1 Stage and Grading   
 Stage and grade information was gathered from the National Comprehensive 
Cancer Network Clinical Practice Guidelines in Oncology, Breast Cancer, version 
2.2012 (NCCN, 2012). Stage and grade are used to classify solid tumors. Both are 
important indicators for prognosis and are useful in determining how a patient is to be 
treated. For instance, if a patient has a low grade and stage tumor, that patient is most 
likely treated with radiation and/or surgical resection, often breast conserving, is 
proposed. Hormone therapy might also be recommended for the patient. Later stage 
and grade tumors are often indicators of poor prognosis and must be treated with 
aggressive chemotherapy when the patient is able to tolerate the high doses. Stage 4 
disease indicate the tumor has metastasized to distant lymph nodes and parts of the 
body, therefore palliative care is the only treatment option in hopes of extending life. 
Common sites of metastasis for breast cancer include the lungs, liver, bones and brain. 
Staging is based on TNM where T is the size of the tumor, N is lymph node 
involvement, and M is the presence or absence of metastasis. T can be subdivided into 
T0 or the absence of a primary tumor; T1 where the tumor is ≤20mm; T2 where the 
tumor is >20mm but ≤50mm; a T3 tumor is >50mm; and T4 in breast cancer indicates 
the tumor has invaded the chest wall and/or skin. Regional lymph node involvement is 
measured as the N staging where N0 is no node involvement; N1 is detectable 
metastasis to a movable ipsilateral level I,II axillary lymph node; N2 in clinically fixed or 
matted ipsilateral level I,II or internal mammary nodes without axillary node detection;  
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Staging is based on TMN system. Lymph node 
involvement within the breast is an important indicator of 
stage and can dictate treatment options. Cancer cells 
detected in the supraclavicular, intraclavicular, and 
internal mammary lymph nodes is more advanced 
disease and staged N3. Image reproduced with 
permission from American Cancer Society. 
Figure 1: Breast lymph nodes.  
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N3 metastasis in ipsilateral infraclavicular (level III axillary), internal mammary nodes, or 
ipsilateral supraclavicular lymph nodes (Figure 1). M is used to indicate the presence or 
absence of metastasis. M0 means there is no detectable distant metastasis in the body 
where M1 is the detection of metastasis, the extent of metastasis is unnecessary for 
TMN staging (NCCN, 2012).  
 Grade is based on the histological characterization of the tumor. G1 indicates a 
low grade where the cancer cells are more differentiated and generally have a more 
favorable prognosis; G2 cells have an intermediate histology where cells are less  
differentiated but the prognosis is still moderately favorable; G3 is the least favorable 
grade and indicates that the tumor cells are poorly differentiated (NCCN, 2012). 
1.1.2 Triple Negative Breast Cancer 
TNBC is a highly malignant and aggressive subtype of breast cancer. While it 
encompasses 12-20% of all diagnosed breast cancers, it is responsible for a disparate 
number of breast cancer related deaths (Chacon and Costanzo, 2010; Schneider et al., 
2008). Premenopausal African American women are likely to develop TNBC at a 
disproportionate rate compared to white counterparts for reasons that are currently 
unknown (Stead et al., 2009). TNBC is characterized by a lack of receptor 
overexpression (ER [estrogen receptor], PR [progesterone receptor], and HER2) and 
therefore the commonly used hormone targeted and HER2 driven antibody therapies 
are ineffective against the subtype. Part of the high mortality rate associated with TNBC 
is due to the aggressive nature of basal-like cancers. A large proportion of TNBC 
tumors are basal-like and often have higher histological grade, a high Ki67 index, 
marked cellular pleomorphism, increased mitotic activity, and atypical mitotic figures 
6	  	  
	  	  
Table 1: Molecular subtypes, characteristics, and treatment. 
 
	  
Molecular 
Subtype 
Biomarker 
Profile 
Clinical Features Treatment 
Luminal A ER+ and/or PR+, 
HER2-, low Ki67 
(<14%) 
~40% of invasive 
breast cancer 
Luminal A. 
Hormone therapy.  
Radiotherapy. 
Chemotherapy 
variable. 
Prognosis better for 
LumA than LumB 
Luminal B  
(HER2+ and 
HER2-) 
Her2-: ER+ and/or 
PR+,HER2-,and 
high Ki67 (>14%) 
Her2+: ER+ 
and/or 
PR+,HER2+, any 
Ki67 
~20% of invasive 
breast cancer 
Luminal B.  
Higher histological 
grade than LumA. 
Hormone therapy.  
Radiotherapy. 
Chemotherapy better 
response in LumB. 
HER2+ ER-, PR-, and 
HER2+ 
HER2 
overexpressed or 
amplified. 
Trastuzumab 
(Herceptin). 
Lapatinib 
Radiotherapy. 
Anthracycline- 
based chemotherapy. 
Poor prognosis 
Basal  ER-, PR-, HER2-, 
and CK5/6 and/or 
EGFR+ 
~80% overlap 
between ‘TNBC’ 
and intrinsic 
‘basal-like’ 
subtype. 
BRCA1 
dysfunction 
Often in African 
Americans. 
Very aggressive 
and highly 
malignant. 
Adriamycin, 
cyclophosphamide, 
taxane.   
Radiotherapy. 
Platinum-based 
chemotherapy. 
PARP inhibitors. 
Poor prognosis. 
The four main molecular subtypes of breast cancer are Luminal A (LumA), Luminal 
B (LumB), HER2+, and Basal. They are characterized by the presence of the 
Estrogen Receptor (ER), the Progesterone Receptor (PR), HER2 Receptor (human 
epidermal growth factor 2), Ki67 (MK167), EGFR, and CK5/6 (cytokeratin 5,6) 
levels (Cheang et al., 2009; Goldhirsch et al., 2011; Nielsen et al., 2004; Schnitt, 
2010). 	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(Nielsen et al., 2004; Rakha et al., 2007). These are all characteristics of higher 
proliferative potential and poorly differentiated tumor cells. Genomic instability and 
increased DNA copy number also contribute to TNBC malignancy (Chin et al., 2006). 
TNBC can contain detrimental mutations in p53, increased expression of immune 
response genes, and/or BRCA1 mutations (Schneider et al., 2008). BRCA1 alterations 
are often associated with TNBC. Mutations in BRCA1 lead to decreased DNA repair 
mechanisms and therefore increased genomic mutations and genetic instability. BRCA1 
and BRCA2 mutations are responsible for 25% of hereditary breast cancers (Easton, 
1999).  90% of all BRCA1 associated tumors are triple negative (Chacon and Costanzo, 
2010). With such heterogeneous characteristics, TNBC is difficult to treat and the 
genomic instability and variety of mutations along with the growth signaling pathway 
alterations make a disease that often develops resistance to many cytotoxic 
chemotherapy agents.  
TNBC can be subdivided into further histological categories (see Table 2), the 
most common type being basal-like. Most TNBC tumors express basal markers such as 
the EGFR (epidermal growth factor receptor) and cytokeratins. Lehman and colleagues 
divided TNBC into 7 subcategories based on differential gene expression. The 
categories can be seen in Table 2 and are as follows: basal-like 1 (BL1); basal-like 2 
(BL2); immunomodulatory (IM); mesenchymal  (M); mesenchymal stem–like (MSL); 
luminal androgen receptor (LAR); and unstable (UNS) (Lehmann et al., 2011). The IM 
subtype has gene expression enriched in the immune cell processes.  IM is 
characterized by immune signaling in addition to immune cell-surface antigens,  
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Table 2: TNBC Subtypes.  	  	  	  
Subtype Associated Pathways 
Basal-like 1 (BL1) Cell Cycle 
DNA replication reactome 
RNA Polymerase 
Basal-like 2 (BL2) EGF Pathway 
NGF Pathway 
MET Pathway 
WNT β-catenin Pathway 
Immunomodulatory 
(IM) 
CTLA4 
IL12 Pathway 
Th1/Th2 Pathway 
IL7 Pathway 
Mesenchymal-like 
(M) 
IGF/mTOR Pathway 
ECM Pathway 
Regulation of Actin by RHO 
WNT Pathway 
Mesenchymal Stem-
like (MSL) 
ECM Receptor Interaction 
TCR Pathway 
WNT β-catenin 
Focal Adhesion 
Luminal AR (LAR) Pentose/Glucuronate 
Interconversion 
Glutathione Metabolism 
Tyrosine Metabolism 
Steroid Biosynthesis 
Unstable (UNS) Cytokeratin Expression 
Multiple chromosome 
rearrangements  
  
  
There are 7 TNBC subtypes that are characterized by 
differential gene expressions; basal-like 1, basal-like 2, 
immunomodulatory, mesenchymal, mesenchymal stem–
like, luminal androgen receptor, and unstable. 
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cytokine signaling, complement cascade, chemokine receptors and ligands, and 
antigen presentation (Lehmann et al., 2011). The M and MSL subtypes are enriched for 
cell motility, ECM receptor interaction, and cell differentiation pathways (Lehmann et 
al., 2011). MSL is also enriched for angiogenesis and claudins. The LAR subtype is 
characterized by increased steroid synthesis,  porphyrin metabolism,  and  
androgen/estrogen metabolism (Lehmann et al., 2011).  The different TNBC subtypes 
have significant variability in relapse-free survival. LAR has a significant decrease in 
relapse-free survival compared to BL1 and IM (Lehmann et al., 2011). The M subtype 
also had a lower relapse-free survival compared to BL1, and that for MSL was greater 
than M. The MSL subtype had the greatest relapse-free survival while patients with the 
LAR subtype had the worst prognosis for relapse-free survival based on Kaplan-Meier 
analysis following the patients for 10 years. Lehmann and colleagues found that there 
was no significant difference in tumor size or grade at diagnosis between the TNBC 
subtypes but women diagnosed with LAR were older compared to the other subtypes 
(Lehmann et al., 2011). 
These following data concerning surgical resection are from cancer.net and 
Kaviani et al., 2013.  Most TNBC tumors are surgically resected with administration of 
adjuvant chemotherapy and radiation (Gangi et al., 2014). Surgery for the treatment of 
breast cancer has changed drastically in the last 30 years. While complete removal of 
the breast and all surrounding tissue was once commonplace and left debilitating scars 
and largely deformed chests, surgery is now able to effectively remove the tumor 
without excising a considerable amount of normal surrounding tissue. The former 
surgery was called a radical mastectomy and the entire breast, muscle, and all 
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surrounding tissue was completely removed, even up through the armpit and into the 
back on certain occasions. The surgery left many women disfigured and reconstruction 
of a new breast was not possible. Surgeons were later able to remove less of the 
normal breast tissue while still getting clean margins around the edges of the tumor, a 
necessity to ensure total removal of cancerous cells in the area. A lumpectomy is now a 
common practice for smaller tumors within the breast allowing for removal of the tumor 
mass while conserving as much normal tissue as possible. This allows for easier 
reconstructive surgery with the remaining tissue and enabling many women to keep the 
appearance of a normal breast. In one study, breast-conserving therapy with whole 
breast radiation had the same survival rate as a mastectomy for TNBC(Gangi et al., 
2014). 
Surgery is most often paired with either radiation and/or chemotherapy in a 
neoadjuvant or adjuvant setting. Neoadjuvant chemotherapy is given to reduce the size 
of the tumor before surgery. If the oncologist is able to reduce tumor burden, less tissue 
can be removed leading to less downtime for the patient and an easier recovery. 
Radiation and adjuvant chemotherapy are often given after surgery to ensure removal 
of microscopic cancer cells that might have been left behind after the surgery (Kaviani 
et al., 2013). TNBC has a greater chance of recurrence after resection than the other 
molecular subtypes of breast cancer, therefore; aggressive chemotherapy and radiation 
are almost always suggested for these patients (Meyers et al., 2011; Zaky et al., 2011).  
Scientists and clinicians are actively working to find a better treatment for women 
with TNBC that helps combat the high rate of treatment resistance and tumor 
recurrence. The current chemotherapy standard of care for TNBC patients is the 
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combination ACT (adriamycin [doxorubicin], cyclophosphamide, and a taxane). Many 
ongoing clinical trials are aimed at exploiting the signaling pathways upregulated in 
TNBC or DNA repair mechanisms, as BRCA1 and PARP1 (Poly[ADP]ribose 
polymerase 1) are often mutated.  A current treatment with a relatively good success 
rate is an aggressive combination of systemic cytotoxic chemotherapy. 5-fluorouracil (5-
FU), doxorubicin and cyclophosphamide was shown to have a 45% pathological 
complete response (pCR) in a 2005 study (Rouzier et al., 2005). Other studies have 
looked at platinums as some TNBCs express BRCA1 mutations, which confer sensitivity 
to cisplatin (Byrski et al., 2010; Silver et al., 2010). PARP1 inhibitors have also shown 
some success in TNBC and many clinical trials are ongoing to assess their efficacy in 
the clinic in Phase I and II trials (NCT01116648, NCT00516724) (Santana-Davila R, 
2010; Tutt et al., 2010). Many chemotherapeutic options exist for TNBC but 
unfortunately they have not delivered high response rates.  
TNBC also expresses receptors that can be inhibited through targeted drugs. 
Unlike systemic cytotoxic chemotherapy, targeted agents are more effective at 
selectively killing the cancer while sparing a greater number of normal cells. Side effects 
of targeted therapies still exist but are often better tolerated than their cytotoxic 
counterparts. Many targeted therapies work on the premise of oncogene addiction. 
Oncogene addiction is the theory that cancer cells rely on the overexpression of certain 
growth factors and receptors, such as EGFR and HER2, therefore when the receptor is 
inhibited the cancer cells are less able to adapt to the inhibition and subsequently die. 
When this signaling is reduced, normal cells can better adjust and therefore survive; 
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opposed to the addicted cancer cells which are more likely to die when the strong 
growth stimulus is removed (Malina et al., 2011; Weinstein, 2002).  
Further trials are ongoing in TNBC using a combination of EGFR inhibitors and 
other cytotoxic chemotherapies such as docetaxel and carboplatin (NCT00491816). 
EGFR inhibitors are approved for treatment of non-small-cell lung carcinoma (NSCLC) 
(Rosenberg et al., 2004). Antibodies such as cetuximab, and tyrosine kinase inhibitors 
(TKIs) such as gefitinib and erlotinib, are used to inhibit the EGFR and its downstream 
effectors. As previously mentioned, EGFR is overexpressed (greater than 3-fold) in 
TNBC, up to 50%, and therefore could be a potential drug target (Nielsen et al., 2004; 
Rakha et al., 2007). Other targets for TNBC therapies are mTOR (mammalian target of 
rapamycin) and VEGF (vascular endothelial growth factor). The mTOR inhibitor, 
everolimus, is being used in clinical trials in metastatic TNBC disease (NCT00827567) 
and in combination with paclitaxel and cisplatin (NCT00930930). VEGF targeted anti-
angiogenic therapy has also been evaluated with bevacizumab with or without paclitaxel 
and/or carboplatin followed by doxorubicin and cyclophosphamide, or bevacizumab as a 
single agent (NCT00861705, NCT00528567). Among pathways that are upregulated in 
TNBC, mTOR is often activated. Studies have shown that EGFR and mTOR inhibitors 
are effective in preclinical models as a combination but their mechanism of action is still 
unknown (Bianco et al., 2008; Liu et al., 2011). The combination of EGFR and mTOR 
inhibitors in TNBC was explored in the clinic, however, all trials were terminated due to 
slow accrual or funding termination before any clinical results were reported. Such trials 
included the combination of lapatinib and everolimus (NCT01272141), which was 
terminated in March 2014. The mTOR inhibitor, rapamycin was shown to sensitize 
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NSCLC cells that have gained resistance to gefitinib and a similar study showed 
everolimus, a rapamycin analog (rapalog), had the same effect (La Monica et al., 2009; 
Liu et al., 2011). Colon, pancreatic, and breast cancer cell lines that were resistant to 
EGFR TKIs were also sensitized when treated with an mTOR inhibitor but the 
mechanism of action is unknown (Bianco et al., 2008; Buck et al., 2006). More about 
EGFR and mTOR will be discussed below in upcoming sections. 
1.2 Epidermal Growth Factor Receptor 
 The epidermal growth factor (EGF) was first discovered in 1962 by Stanley 
Cohen as an agent that promoted eye opening in newborn mice (Cohen and Carpenter, 
1975). Years later Graham Carpenter discovered the receptor (Carpenter et al., 1978). 
The EGFR is part of the ErbB/HER family of transmembrane growth factor receptors, 
which include four members: EGFR, also known as ErbB1/HER1, ErbB2⁄HER2⁄NEU, 
ErbB3⁄HER3, and ErbB4⁄HER4 (Mitsudomi and Yatabe, 2010) (Figure 2). The 
deregulation of ErbB (erythroblast leukemia viral oncogene) proteins have been 
implicated in the tumorigenesis of many epithelial cancers including lung, breast, 
ovarian, pancreatic, and prostate (Hynes and Stern, 1994).  
ErbB proteins have four functional domains including a cysteine-rich extracellular 
ligand-binding domain, a transmembrane domain, an intracellular tyrosine kinase 
domain, and a C-terminal regulatory domain (Burgess et al., 2003; Hynes and Lane, 
2005; Riese and Stern, 1998). The ErbB family of receptor tyrosine kinases are 
activated in response to a ligand, homo- or heterodimerize, and activate downstream 
signaling pathways through tyrosine phosphorylation of different residues on the 
intracellular domain (Riese and Stern, 1998). The heterodimerization enables the 
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orphan receptor ErbB2/HER2 and the kinase-dead ErbB3/HER3, to initiate signaling 
through binding the other family members (Hynes and Lane, 2005). Downstream 
pathways activated by the ErbB family include the mitogen-activated protein kinases 
(MAPK) cascade (Figure 3 EGFR Y1148) and phosphatidylinositide 3-kinases (PI3K) 
activated AKT pathway cascade (Figure 3, EGFR Y1101). Y1148 and Y1101 
correspond with the site on the EGFR that when phosphorylated allows for binding and 
activation of the respective proteins. P70S6K (70kDA Ribosomal protein S6 kinase) can 
also be activated directly by ErbB3 and ErbB4 dimers and indirectly through ErbB1 and 
ErbB2 (Yarden and Sliwkowski, 2001).  
The four members of the ErbB family can be activated through eight ligands 
grouped into three different classes (Figure 2). The first class can only bind EGFR and 
contains EGF and its analogs, transforming growth factor alpha (TGF-α) and 
amphiregulin (AR), also known as keratinocyte autocrine factor or colorectum-cell 
derived growth factor. The second class can bind ErbB3 and ErbB4 and contains the 
neuregulins (NRGs) and the neuregulin-2s (NRG-2s), also known as the cerebellum-
derived growth factors. The final group can bind both EGFR and ErbB4 and contain 
heparin-binding epidermal growth factor-like factor (HB-EGF), epiregulin (EPR); 
betacellulin (BTC); also known as heregulins (Riese and Stern, 1998). The ErbB family 
can also be activated through receptors and signals that do not directly interact with 
EGFR. These include hormones, neurotransmitters, lymphokines, and stress inducer 
signals demonstrating the diversity of the receptor and its activators (Carpenter, 1999).   
  The EGFR signaling cascade has been extensively studied as it plays a major 
role is many aspects of normal cellular processes including apoptosis, migration, 
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growth, adhesion, and differentiation (Figure 2) (Yarden and Sliwkowski, 2001; Yecies 
and Manning, 2011). Both the ligand and dimerization partner determines the output 
signal from ErbB family members. This interaction allows for the autophosphorylation of 
ErbB, recruiting the specific docking proteins to sites of phosphorylation to begin the 
signaling cascade (Olayioye et al., 1998). There are three pathways that can be 
activated by all ErbB dimerization couples. These include the Ras activated MAPK 
cascade, PI3K/ AKT pathway, and P70S6K/p85S6K (Soltoff and Cantley, 1996; Yarden 
and Sliwkowski, 2001). While all dimers can activate these pathways, they require 
certain docking proteins that can only interact with specific dimers. For example, c-Cbl 
is unable to interact with ErbB3, and the receptor is also unable to bind PLCγ, and Grb2 
affecting ErbB3’s ability to ubiquitinate and activate the transcription factor Fos (Fedi et 
al., 1994). ErbBs can also be trans-activated by GPCRs and heterologous signals 
including hormones, neurotransmitters, lymphokines, and stress inducers. Non-receptor 
tyrosine kinases such as JAK are also able to directly phosphorylate the kinase part of 
the receptor resulting in activation of EGFR dependent pathways (Carpenter, 1999; 
Yarden and Sliwkowski, 2001). Most of what is known about ErbB signaling results in 
growth and proliferation. Our data suggest that the EGFR pathway also may play a role 
in translation through a lesser known and explored mechanism involving eukaryotic 
initiation factor 4B (eIF4B). The EGFR function in translation closely links the pathway 
with mTOR’s involvement in the same process and provides a potential pathway 
crosstalk that is important in TNBC and that this dissertation explores.  
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 Knockout mice of EGFR have proven its vital role in skin, lungs, and the 
gastrointestinal tract with knockout of the receptor being embryonic lethal (Miettinen et 
al., 1995; Sibilia and Wagner, 1995; Threadgill et al., 1995). Of the many pathways that 
EGFR is involved in; much research has been done with the EGFR as a typical receptor 
tyrosine kinase (RTK) and the start of the RAS/RAF/MEK/ERK cascade (Yarden and 
Sliwkowski, 2001). Studying the activation of proteins within the cascade has helped to 
understand a substantial amount about RTK signaling through phosphorylation.   
  HER2 is amplified in 15-30% of invasive ductal carcinomas (Slamon et al., 1987). 
Tumors with higher levels of HER2 are generally larger at diagnosis, have greater 
lymph node involvement, higher grade, and contain a greater number of proliferative 
cells (Yarden and Sliwkowski, 2001). The recognition of HER2 as a druggable target led 
to the generation of an antibody to HER2 in 1998, known as herceptin (trastuzumab). 
The antibody has been effective at reducing tumor burden in patients with HER2 
overexpression through binding and subsequent inhibition of downstream pathways and 
internalization. It also induces expression of the cyclin dependent inhibitors, p27Kip1 and 
p130, which inhibit the cell cycle, and recruit immune cells (Clynes et al., 2000; 
Sliwkowski et al., 1999).   
1.2.1 EGFR as a Target in Cancer 
 Kawamoto and Sato first explored targeting EGFR in cancer in 1983 when they 
studied growth inhibition of tumor cells treated with an EGFR antibody (Kawamoto et al., 
1983; Sato et al., 1983). Their experiments had promising results and others since have 
also studied inhibition of the EGFR and its downstream signaling pathways in most solid 
tumor types (Herbst et al., 2004; Mitsudomi and Yatabe, 2010). The EGFR is involved in   
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Figure 2: ErbB family members, ligands, and signaling network.  
 
	  	  	  
The ErbB family contains four members; EGFR, Her2, Her3, and Her4. Upon ligand 
stimulation the receptors homo- or heterodimerize, cross phosphorylate and activate 
downstream signaling pathways through tyrosine kinase activity.  Her2 has no ligand 
but can dimerize with the other family members while Her3 has no kinase activity and 
therefore must heterodimerize with another family member to signal after ligand binding. 
This figure is reproduced with permission from Yarden and Sliwkowski, 2001. 	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Figure 3: EGFR phosphorylation sites. 
 
 
	  
Many sites on the EGFR that, when phosphorylated, induce receptor signaling to a 
variety of known proteins. The signaling is further propagated through kinases leading 
to pathway activation including cell growth and proliferation. Figure is reproduced with 
permission from Wheeler et al., 2010.  
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a complex array of signaling networks. It signals for cell proliferation, apoptosis, 
adhesion, differentiation, migration, survival, angiogenesis, and tumorigenesis (Wheeler 
et al., 2010; Yarden and Sliwkowski, 2001). Its overexpression has been found as a 
driving factor in head and neck, breast, bladder, prostate, kidney cancers, NSCLC, and 
gliomas (Yarden and Sliwkowski, 2001). It also might be a prognostic indicator in 
bladder, prostate cancers, and NSCLC (Gorgoulis et al., 1992; Irish and Bernstein, 
1993). In breast cancer it has been found to be a predictor of recurrence after surgical 
resection and associated with a shorter disease free and overall survival. The anti-
proliferative ability of EGFR inhibitors was very promising and led the FDA to approve 
five different EGFR inhibitors within three years (gefitinib 2003 for NSCLC, cetuximab 
2004 for colorectal cancer, erlotinib 2004 for NSCLC and pancreatic cancer, 
panitumumab 2006 for colorectal cancer, laptinib 2006 for breast cancer) (Wheeler et 
al., 2010). EGFR inhibitors are effective in these cancers as a common mutation in the 
EGFR confers sensitivity to the drugs (L858R). This same mutation is not seen in breast 
cancer and therefore leads to resistance to EGFR inhibitors. Since then, EGFR 
inhibitors have been used to treat a variety of cancers including lung, colorectal, 
pancreatic, and head and neck (Chong and Janne, 2013). One of the most notable 
advances is the use of gefitinib and erolitinib to treat metastatic lung cancer patients. 
The patients treated with gefitinib or erolitinib had a 74% and 83% response rate 
respectively, compared to the other best treatment with progression free survival and 
overall survival rates in the 30% (Inoue et al., 2013; Maemondo et al., 2010; Zhou et al., 
2011). The effectiveness of inhibiting the receptor has made EGFR inhibitors part of 
standard treatment for NSCLC with increased expression of EGFR.   
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Figure 4: Binding sites of EGFR inhibitors.  
 
 
  
The EGFR is a transmembrane receptor that, upon ligand binding, 
dimerizes and cross phosphorylates to signal. The extracellular side 
of the receptor binds the ligand and anti-EGFR antibodies such as 
cetuximab and panitumumab. TKIs inhibit the intracellular kinase 
activty of the receptor. These small molecules include gefitinib (used 
in this dissertation work), erlotinib, AZD9291, and CLO-1686. This 
figure was reproduced with permission from Arteaga and Engelman, 
2014. 
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Two different classes of EGFR inhibitors are used in the clinic, TKIs and 
antibodies. TKIs target the kinase activity of EGFR through ATP competitive binding 
and include erlotinib, lapatinib, and gefitinib. Monoclonal antibodies, which bind the 
receptor to inhibit its activity and promote receptor internalization include cetuximab and 
panitumumab (Chong and Janne, 2013) (Figure 4). Gefitinib is prescribed in the clinic 
as a 250mg orally available drug that is used daily at a lower concentration than the 
maximum tolerated dose resulting in less toxicity (Rukazenkov et al., 2009). Like many 
other targeted therapies, gefitinib and erolitinib have a more favorable side-effect profile 
then cytotoxics, which often have nausea, diarrhea, and neuropathy as limiting 
toxicities. Common reported adverse events with gefitinib are rash and diarrhea 
(Maemondo et al., 2010).  
There are a multitude of other EGFR inhibitors available for clinical use and 
many still waiting for FDA approval. While single agent treatment with EGFR inhibitors 
in cancers have not proven to be very effective due to their high levels of resistance, 
discussed below, the combination of EGFR inhibitors along with cytotoxic chemotherapy 
has proven promising in colorectal and metastatic pancreatic cancers, and especially in 
lung cancer (Chong and Janne, 2013; Gschwind et al., 2004). 
1.2.2 Mechanisms of Resistance  
 EGFR inhibitors have been used in the clinic for a variety of cancer types. While 
EGFR is a druggable target, its intricate signaling pathways and wide variety of ligands 
often allow the cell to remain activated while the EGFR is inhibited. This resistance can 
either be acquired or de novo. Acquired resistance occurs when the cell is able to 
activate other proteins to compensate for EGFR inactivation. De novo resistance is 
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present at onset enabling the cell to completely be independent of EGFR signaling 
inhibition with minimal new activation of compensatory mechanisms as seen in acquired 
resistance. There are many different ways that cells can circumvent EGFR inhibitors for 
either de novo or acquired resistance that are discussed below.  
 Receptor mutations play an important role in determining sensitivity to EGFR 
inhibitors. In the clinic, patients with certain EGFR mutations are more sensitive to 
inhibitors while other mutations render resistance. One resistance mutation was 
identified in glioblastoma multiforme (GBM) patients who developed insensitivity to 
gefitinib. The mutation was a constitutively active truncated version of the receptor 
known as EGFRvIII (Wheeler et al., 2010). Another common mutation that patients 
develop after prolonged treatment of EGFR TKIs is a substitution in exon 20, T790M. 
This residue is considered a “gatekeeper” for the ATP-binding pocket of EGFR. 
Resistance may occur when the TKI is no longer able to bind the pocket on the EGFR 
due to the larger methionine group and subsequent steric interference (Kobayashi et al., 
2005; Pao et al., 2005).  
Angiogenesis is activated by EGFR signaling and is a process that is necessary 
for tumor growth and metastasis.  During tumor vascularization, blood vessels grow into 
the tumor, bringing it nutrients and providing a mechanism for individual tumor cells to 
circulate through the body and metastasize. VEGF is a ligand that is necessary to 
support angiogenesis and tumors resistant to EGFR inhibitors are known to upregulate 
VEGF and its receptor, VEGFR (Viloria-Petit et al., 2001). Activation of the PI3K/AKT 
pathway was also found in NSCLC patients who were resistant to gefitinib. Researchers 
found that EGFR was coupled to ErbB3 and could activate AKT only in cell lines that 
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are sensitive to gefitinib. Gefitinib binds the EGFR/ErbB3 complex and inhibits PI3K 
association therefore decreasing AKT activity. The association of ErbB3 and PI3K is not 
seen in resistant cell lines and allows AKT to remain active as it is not inhibited when 
gefitinib binds the ErbB dimer (Engelman et al., 2005). The receptor c-Met (MNNG HOS 
transforming gene) is overexpressed in NSCLCs that are resistant to EGFR inhibitors.  
c-Met also plays a role in breast cancer resistance to EGFR TKIs, as it was found to 
activate EGFR substrates in the presence of EGFR inhibitors (Mueller et al., 2010; 
Mueller et al., 2008). AKT is also activated through overexpression of c-Met in lung 
cancer (Engelman et al., 2007). Ubiquitination is known to mediate resistance to 
cetuximab as decreased receptors on the cell membrane still elicit a strong EGFR 
signaling response and ubiquitin levels can determine receptor recycling or degradation 
(Lu et al., 2007; Wheeler et al., 2008). IGFR-1 (insulin-like growth factor receptor 1) 
activation is also shown to mediate resistance to EGFR inhibitors through activation of 
AKT and P70S6K (Chakravarti et al., 2002). Epithelial to mesenchymal transition (EMT) 
plays a role EGFR inhibitor resistance as mesenchymal type cells rely minimally on 
EGFR signaling (Wheeler et al., 2010). While EGFR inhibitors are used in the clinic, 
many studies have found a variety of mechanisms in vitro allowing the cell to 
compensate for EGFR inhibition leading to resistance. These studies can allow 
researchers and physicians to further explore combination therapies of EGFR inhibitors 
and a drug that targets one of the known mechanisms of resistance.  
1.3 PI3K/AKT/mTOR 
AKT/PKB has been implicated in a variety of processes that lead to 
tumorigenesis (Faivre et al., 2006; Fresno Vara et al., 2004). Hannahan and Weinberg 
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designated six different hallmarks of cancer and AKT is involved in all. (1) Growth signal 
autonomy: AKT overexpression or activation leads to signaling with a low amount of 
growth factors, (2) Insensitivity to antiproliferative signals: Recruits Mdm2 (mouse 
double minute 2 homolog) to the nucleus to inhibit p53, localizes p21Cip/Waf1 to promote 
proliferation, and stabilizes Cyclin D1 to promote cell cycle progression, (3) Inhibition of 
apoptosis: Inactivates Bad (Bcl-2-associated death promoter), procaspase-9, NF-ΚB 
(nuclear factor kappa-light-chain-enhancer of activated B cells), and Fas ligand, (4) 
Unlimited replicative potential: Phosphorylates hTERT (human telomerase reverse 
transcriptase) to increase telomeres, (5) Angiogenesis: Promotes through eNOS 
(endothelial nitric oxide synthase), (6) Invasion and metastasis: Inhibits anoikis and 
stimulates MMP (matrix metalloproteinases) secretion to increase basement membrane 
degradation (Fresno Vara et al., 2004).  
AKT has three homologous isoforms (AKT1, AKT2, and AKT3) each with four 
domains: a plekstrin homology (PH) domain, an N-terminal domain, kinase domain, and 
a C-terminal domain (Alessi et al., 1996; Hay and Sonenberg, 2004). Full activation of 
AKT requires phosphorylation of Thr308 and Ser473 through amino acid, glucose, and 
oxygen and/or mitogen (hormone and growth factor) stimuli (Alessi et al., 1996; 
Engelman, 2009). Activated AKT can then signal through the mTOR complexes by 
binding to TSC2 and acting as a GAP (GTPase-activating protein) for the GTPase Rheb 
(Hay and Sonenberg, 2004). Two complexes contain the mTOR protein, mTORC1 
(mammalian target of rapamycin complex 1 [containing Raptor]) and mTORC2 
(mammalian target of rapamycin complex 2 [containing Rictor]).  Not much is known 
about the regulation and function of mTORC2 but it contains 6 subunits; mTOR,  
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Figure 5: mTOR is involved in multiple cellular processes.  
 
	  
mTOR is involved in many components of the cell. It signals for energy and protein 
homeostasis within the cell. This figure is reproduced with permission from Yecies and 
Manning, 2011.  
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rapamycin-insensitive companion of mTOR  (Rictor), mammalian stress-activated 
protein kinase interacting protein (mSIN1), protein observed with Rictor-1 (Protor-1), 
mammalian lethal with Sec13 protein 8 (mLST8, also known as GbL), and DEP-domain-
containing mTOR-interacting protein Deptor (Laplante and Sabatini, 2009). Data 
suggest that it phosphorylates the AGC kinase family, including AKT leading to a 
feedback loop, protein kinase C alpha (PKCα), and the serum/glucocorticoid regulated 
kinase 1 (SGK1) (Guertin and Sabatini, 2007). It also leads to actin regulation, 
cytoskeleton formation and cell survival (Sarbassov et al., 2004). mTORC1 (known as 
simply mTOR for the purposes of this dissertation) is involved in growth, proliferation, 
autophagy, and translation (Ganley et al., 2009; Laplante and Sabatini, 2009). It is 
comprised of five subunits: mTOR, regulatory-associated protein of mTOR (Raptor), 
mLST8, proline-rich AKT substrate 40 kDa  (PRAS40), and (Deptor) (Laplante and 
Sabatini, 2009). 
mTOR activates P70S6K, which phosphorylates 4E-BP1 (eukaryotic translation 
initiation factor 4E-binding protein 1) to remove it from eIF4E, (eukaryotic translation 
initiation factor 4E)  releasing the translation initiation factor allowing it to complex with 
eIF4A (eukaryotic translation initiation factor 4A), and eIF4G (eukaryotic translation 
initiation factor 4G) to form eIF4F (eukaryotic translation initiation factor 4F) and 
stimulate translation. A more extensive review of translation initiation will follow in 
Section 1.4. mTOR is also able to stimulate translation through phosphorylating eIF4B 
allowing it to facilitate eIF4A helicase activity. Important tumorigenic proteins translated 
through this mechanism are cell cycle regulating proteins, HIF-1α (hypoxia-inducible 
factor 1-alpha), FGF (fibroblast growth factor), VEGF (vascular endothelial growth 
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factor), STAT3 (signal transducer and activator of transcription 3), and c-Myc 
(Strimpakos et al., 2009). mTOR is also involved in lipid biogenesis in the mitochondria 
(Laplante and Sabatini, 2009; Schieke et al., 2006). Within the mitochondria, mTOR 
affects mitochondrial membrane potential, oxygen consumption and cellular ATP levels 
(Schieke et al., 2006). A complex signaling network activates mTOR and it can sense a 
plethora of stimuli such as amino acids, mitogens, oxygen, stress, and inflammation to 
generate a cellular response (Guertin and Sabatini, 2007; Hardie et al., 1998; Wouters 
and Koritzinsky, 2008) (Figure 5). 
Upstream of AKT is PI3K. The protein is a heterodimer comprising a catalytic 
subunit (p110) and a regulatory subunit (p85) (Hay and Sonenberg, 2004). PI3K is 
responsible for converting phosphatidylinositol-4,5-bisphosphate (PI-4,5-P2) to 
phosphatidylinositol-3,4,5-trisphosphate (PI-3,4,5-P3). PIP3 then activates AKT through 
the PH domain and phosphorylation by 3-phosphoinositide-dependent kinase-1 (PDK1). 
The dephosphatase PTEN converts the second messenger, PIP3, back to the PIP2 
form (Fresno Vara et al., 2004).  
1.4 Protein Translation 
 All cells need the production of proteins for normal cellular functions. Cancer 
cells have a larger requirement for proteins in order to maintain their high metabolic rate 
and uncontrolled growth and proliferation. It was first observed that cancer cells have 
larger and more numerous nucleoli, the location of ribosome assembly in 1976 (Gani, 
1976). Scientists then found that translation is hyperactive in most cancer cells and the 
proteins that control the process are often deregulated (Johnson et al., 1976; Silvera et 
al., 2010). Due to the greater need for more numerous proteins in cancer cells, efforts 
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are underway trying to target translational control in cancer. If the protein pool within the 
cell could be decreased through inhibiting translation, then it is possible that the cell 
would be unable to grow and proliferate even in the presence of tumorigenic stimuli due 
to a lack of effector proteins. There are three steps in protein translation: initiation, 
elongation, and termination. Most of the regulation occurs at the initiation step and 
many drugs have been synthesized to target specific components of the process.  
There are two types of translation: cap-dependent, which will be discussed immediately 
below, and cap-independent, which will follow.  
Cap-dependent translation is used for the synthesis of 95-97% of all proteins in 
eukaryotes (Merrick, 2004). The name derives from the mRNA cap of a 
guanine nucleotide attached to the mRNA via a 5′ to 5′ triphosphate bond. It requires 
the eukaryotic initiation factors (eIFs). Translation initiation is controlled through the 
eIF2, eIF3, and eIF4 families (Figure 6). Step 1 begins with the 80S ribosome 
dissociating and binding to the ternary complex of a 60S ribosomal subunit, eIF3 and 
eIF41A, and the 40S small ribosomal subunit. This 43S complex then binds with 
methionyl tRNA (Met-tRNAi) as Step 2 (Gingras et al., 1999; Silvera et al., 2010). Step 3 
is binding to the mRNA 5’ end through ATP hydrolysis and to the eIF4F complex 
containing eIF4E, eIF4G, and eIF4A (Gingras et al., 1999; Merrick, 2004). The RNA 
then binds the 43S complex as Step 4. eIF4B facilitates eIF4A helicase activity. Step 5 
is the release of eIF4 family by a GTPase-activating protein (GAP), eIF5 and eIF2, and 
scanning to find the AUG start codon as the 48S. In Step 6 all the initiation factors are 
released and the 60S subunit joins the 40S and starts elongation as the 80S initiation 
complex (Gingras et al., 1999; Merrick, 2004). At the end of initiation the 80S ribosome 
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is attached to the start codon (Dever and Green, 2012). The second codon is in the A 
site on the ribosome and a GTP is needed to attach the tRNA through the eukaryotic 
elongation factor 1A (eEF1A). Elongation is the process of attaching all the aminoacyl-
tRNA, which match with the RNA codons. The process repeats itself until reaching a 
stop codon.  
The codon recognizes its respective aminoacyl-tRNA then the hydrolyses of a 
GTP moves the codon to the next site, P, in the ribosome leaving eEF1A to release and 
allowing a peptide-peptide bond to form between the peptide in P, currently the start 
codon and the A site (Dever and Green, 2012). eEF2 moves the peptides along to the E 
and P sites and the A position opens with a new codon ready to attach to the tRNA. The 
process continues until a stop codon UAA, UGA, or UAG.  Termination requires the 
factors eRF1 and eRF3. eRF1 recognizes the stop codon and causes peptidyl-tRNA 
hydrolysis while eRF3 is a GTPase allowing for separation of the ribosome from the 
newly synthesized peptide and RNA (Atkinson et al., 2008; Dever and Green, 2012). 
Translation is a highly regulated process, which cancer cells often misregulate in 
order to achieve the high number of proteins they require to sustain high metabolic                      
and proliferative rates. While translation initiation is the most regulated step in 
translation and most drugs that target translation aim at the initiation factors, it is 
important to understand the whole process of translation and how cancer is able to 
exploit it.  Ribosomal disorders are linked with an increased risk for developing certain 
types of cancers (Loreni et al., 2013). Table 3 describes common ribosomal disorders, 
the altered genes leading to the disease, and common cancers resulting from the 
mutation. The most common cancers associated with ribosomal disorders include 
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leukemias and lymphomas. For example, Diamond Blackfan anemia is associated with 
an increased risk for many different types of cancer including MDS (myelodysplastic 
syndrome), AML (acute myeloid leukemia), colon adenocarcinoma, osteogenic 
sarcoma, and genital cancer. This disorder is characterized by mutations in many 
ribosomal proteins (RPS), which comprise the 40S ribosome (Loreni et al., 2013). When 
the 40S ribosome is improperly formed, it affects hematopoietic cell lineage resulting in 
red blood cells that are immature and unable to properly bind iron leading to anemia 
and an increased risk for leukemias (Boria et al., 2010). Cartilage hair hypoplasia is 
another ribosome disorder that causes abnormal bone growth resulting in dwarfism. 
Patients also have brittle and sparse hair, weak nails, and immune deficiency. In 
comparison to Diamond Blackfan anemia, patients with Cartilage hair hypoplasia have a 
deficiency in RMRP, which produces a noncoding RNA (Loreni et al., 2013). RMRP is 
part of an enzyme complex called mitochondrial RNA-processing endoribonuclease, or 
RNase MRP. RNase MRP is thought to be involved in mitochondrial DNA replication 
and process ribosomal RNA. These patients often develop Non-Hodgkin’s lymphoma 
and basal cell carcinoma along with gastrointestinal problems including celiac disease 
(Hermanns et al., 2005).  
Cap-independent translation (internal ribosome entry site; IRES) does not require 
the use of the eIF4G mediated RNA binding cap (Silvera et al., 2010). Some mRNAs 
have IRES sequences where the translation initiation factors can bind without the help 
of the highly regulated eIF4F complex (Barna et al., 2008). Some of the mRNAs that 
contain the IRES are involved in tumor progression and metastasis including vascular 
endothelial growth factor A (VEGFA), fibroblast growth factor 2 (FGF2), BCL-2, X-linked 
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inhibitor of apoptosis (XIAP), and HIF-1α (Braunstein et al., 2007). IRES-mediated 
translation can also confer resistance to radiation through upregulation of the 
antiapoptotic protein XIAP (Holcik et al., 2000). BCL-2 and XIAP are upregulated during 
chromosomal instability caused by radiation and chemotherapy, and can support cancer 
development, leading to drug resistance and increased tumorigenesis (Silvera et al., 
2010). Translational control is important in regulating cellular proteins that can support a 
proliferative phenotype.  
1.4.1 eIF4 
 Important to this dissertation is the eIF4 family of initiation factors and their role in 
regulating translation. As mentioned above they are required for cap-dependent 
translation. There are six members in the eIF4 family eIF4A, eIF4A1, eIF4B, eIF4E, 
eIF4G, and eIF4H. eIF4A and eIF4A1 are helicases that are responsible for unwinding 
the mRNA during translation (Parsyan et al., 2011). eIF4B, a major protein of interest in 
this dissertation, facilitates eIF4A helicase activity making it much more efficient and 
promotes the interaction of mRNA-rRNA-Met-tRNAi at the start codon (Gingras et al., 
1999). eIF4E has been the subject of extensive investigation (Gingras et al., 1999; 
Wendel et al., 2004). It is considered an oncogene and is the rate limiting protein and 
step in translation initiation. eIF4E is often sequestered by 4E-BP1 rendering it inactive 
and only when 4E-BP1 is phosphorylated by activated mTOR does eIF4E release and 
allow it to bind to eIF4G and eIF4A to form the eIF4F complex binding it to the mRNA 
and starting translation initiation (Gingras et al., 1999; Wendel et al., 2004). eIF4G is a 
scaffolding protein for the eIF4F complex and eIF4H has similar homology to eIF4B but 
little is known about its function (Gingras et al., 1999).  
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Figure 6: Cap-dependent translation initiation.  
 
	  	  	  	  	  	  	  	  	  	  	  	   	  
   
 
 
 
The eIF4 family is required to assemble the translation initiation complex in 
cap-dependent translation. Translation is comprised of three steps; initiation, 
elongation, and termination. Cap-dependent translation requires the eIF4 
family including eIF4B while cap-independent does not. Figure reproduced 
with permission from Merrick, 2004. 
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Table 3: Ribosomal disorders linked to cancer.	  
 
Disease 
 
Altered 
gene 
 
Cancer Association 
Diamond Blackfan 
anemia 
RPS 
7,10,17,
19,24,26
,RPL5, 
11, 35A 
MDS, AML, colon 
adenocarcinoma, 
osteogenic sarcoma, 
genital cancer 
X-linked 
dyskeratosis 
congenita 
DKC1 AML, head and neck 
tumors 
Sq-syndrome RPS14 AML 
Shwachman-
Diamond 
syndrome 
SBDS MDS, AML 
Cartilage hair 
hypoplasia 
RMRP Non-Hodgkin 
lymphoma, basal cell 
carcinoma 
 
 
 
  
  
Many ribosomopathies confer an increased risk for developing cancer. Aberrant 
translation can lead to abnormal amounts of available protein within the cell 
leading to increased proliferation and genetic instability.  Abbreviations: AML, 
acute myeloid lymphoma; MDS, myelodysplastic syndrome. Table reproduced 
with permission from Loreni et al., 2013.  	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eIF4B is important in the translation initiation process. While it is not the rate-
limiting step or considered an oncogene like eIF4E, it is responsible for the efficiency of 
the eIF4A helicase and is important to translation initiation (Gingras et al., 1999; 
Shahbazian et al., 2010b). eIF4B is phosphorylated by two kinases on Ser422, P70S6K 
and P90RSK (90kDa ribosomal s6 kinase, RSK) (Raught et al., 2004). P70S6K is 
directly activated through mTOR while P90RSK is activated downstream of EGFR and 
the MAPK cascade (Serra et al., 2013). eIF4B seems to be a point of convergence 
between EGFR and mTOR further giving evidence to a complex network of signaling 
cascades (Raught et al., 2004). The extensive crosstalk gives further validation that 
multiple pathways must be inhibited for cancer to respond to treatment.  
1.4.2 Ribosomal S6 Kinases 
 P70S6K is a serine/threonine kinase that is phosphorylated by mTOR and has 
two homologs, S6K1 and S6K2 (Shima et al., 1998). It is a major protein in mTOR 
control of translation through activating required proteins including elongation factors, 
and poly(A)-binding protein (PABP) (Meyuhas, 2000). It also phosphorylates ribosomal 
protein S6 (rpS6), tumor suppressor protein PDCD4, eIF4B, and translation elongation   
factor   eEF2   kinase (Korets et al., 2011). The kinase therefore plays a role in both the 
translation initiation and elongation stages. One of the most extensively studied proteins 
activated by P70S6K is rpS6. Knockout studies in vitro and in vivo demonstrate that the 
protein, a member of the 40S ribosomal subunit, is important in binding the mRNA to 
tRNA between the large and small ribosome (Nygard and Nilsson, 1990). Also of note, 
eIF4B is activated by P70S6K and P90RSK in response to a multitude of extracellular 
stimuli, which promote cell growth and proliferation such as serum, insulin, and phorbol 
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esters (Duncan and Hershey, 1985). rpS6 and eIF4B are two examples of proteins that 
demonstrate the extensive crosstalk between signaling pathways within the cell. They 
are regulated by both the mTOR and MAPK pathways and therefore can detect signals 
from a wide range of inputs.  
 P90RSK is a kinase that is directly phosphorylated by MAPK downstream of the 
Ras-MAPK pathway and therefore EGFR. It has a similar motif to S6K and AKT 
phosphorylating proteins with a basophilic motif RxRxxS/T (R, arginine; S, serine; T, 
threonine; and x, any amino acid) (Manning and Cantley, 2007). The similar motif 
explains the crosstalk mentioned above. P90RSK is also capable of activating rpS6 at 
Ser235/236 and eIF4B at Ser422 independent of mTOR activity, opening the door for 
EGFR control of translation through recruitment of the initiation complex (Roux et al., 
2007). Another example of P90RSK and mTOR crosstalk is the ability of P90RSK to 
phosphorylate TSC2 thereby inactivating it and modulating mTOR activity (Roux et al., 
2004).  
 P90RSK has four isoforms in mammals RSK1-4 which are activated by 
extracellular signal-regulated kinase-1 and -2 (ERK1/2) in response to many 
extracellular signals including growth factors, hormones, neurotransmitters, and 
chemokines (Chen et al., 1992). RSK1 and 2 are known to be activated in breast cancer 
(Clark et al., 2005). RSK contains kinase domains, a linker region, and N- and C-
terminal tails (Anjum and Blenis, 2008). The N-terminal kinase is homologous to ACG 
family kinases including PKA, PKG, and PKC and phosphorylates substrates, while the 
C-terminal domain is similar to the calcium/calmodulin-dependent protein kinases and is 
responsible for the auto-phosphorylation ability of RSK (Bjorbaek et al., 1995; Fisher 
36	  	  
	  	  
and Blenis, 1996). P90RSK is primarily activated by EGFR through the Ras-MAPK 
cascade but it can also be activated by p38 MAPK, the ERK5 MAPK and fibroblast 
growth factor receptor-3 (FGFR3) (Anjum and Blenis, 2008).  
P90RSK is involved in translation as mentioned above through phosphorylation 
of rpS6 and eIF4B but is also plays a role in transcriptional regulation, cell-cycle 
regulation, and cell survival (Roux and Blenis, 2004). P90RSK is known to activate 
transcription factors including CREB, ERα, NF-κB, and transcription initiation factor 
TIF1A (Frodin and Gammeltoft, 1999; Roux and Blenis, 2004). It also regulates Fos and 
Jun and through CREB regulation, P90RSK also controls Signal transducer and 
activator of transcription 3 (STAT3) activation (Anjum and Blenis, 2008; Chen et al., 
1993). P90RSK has a hand in cell survival through the phosphorylation and inactivation 
of Bad, disabling Bad’s ability to inhibit the pro-survival protein, BCL-XL (Shimamura et 
al., 2000). P90RSK also controls cell cycle progression through regulating p27, a cyclin-
dependent kinase inhibitor, allowing G1 progression (Anjum and Blenis, 2008). G2-M 
phase also is regulated through P90RSK and its ability to inhibit Myt1 kinase allowing 
progression into meiosis as demonstrated in Xenopus laevis oocytes (Palmer et al., 
1998).    
1.5 STAT3 
STAT3 is a transcription factor that can be activated by a variety of signaling 
proteins including membrane receptors, i.e., EGFR, and other kinases, i.e., mTOR 
(Figure 7). The STAT family has seven members including STAT1, STAT2, STAT3, 
STAT4, STAT5a, STAT5b, and STAT6 (Quesnelle et al., 2007). Janus kinases (JAKs) 
are intermediary kinases that often activate STATs. Cell surface receptors such as 
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PDGFR, EGFR, and FLT3 can activate the transcription factors through 
phosphorylation. They can also be activated through non-receptor protein tyrosine 
kinases such as c-Src, Bcr-Abl, and mTOR (Buettner et al., 2002). Once activated, 
STATs dimerize and translocate to the nucleus where they recruit cofactors to then bind 
the DNA at STAT3 specific binding sites resulting in transcription. The wide range of 
interacting proteins and different mechanisms of activation demonstrate the broad 
network to which the transcription factors are connected. 
While most is known about STAT5 and STAT3 as they are associated with 
cancer, the STAT family shares common features (Buettner et al., 2002). Once 
phosphorylated STATs can either homo- or heterodimerize and translocate to the 
nucleus where they exert their control on gene expression (Furqan et al., 2013). Each 
STAT is transcribed by a separate gene but they have six conserved domains: an N-
terminal oligomerization domain, a coiled coil, a DNA binding domain, a linker domain, 
an SH2 domain, and a C-terminal transactivation domain (Furqan et al., 2013).    
STAT2, 4, & 6 are known to regulate immune response while STAT1, 3, and 5 are 
involved in cell cycle, survival and angiogenesis (Furqan et al., 2013).  
STAT3 is often considered an oncogene due to its ability to drive tumor formation 
in mice when constitutively activated (Bromberg et al., 1999). STAT3 has been 
implicated in cancer progression for many years and is the most researched member of 
the STAT family. Its overexpression has been found in lung, gastric, breast and 
colorectal cancers and is associated with a poor prognosis (Haura et al., 2005; Kusaba 
et al., 2005; Sheen-Chen et al., 2008; Yakata et al., 2007). STAT3 is involved in cell 
cycle regulation through activation of transcription of CyclinD1, CyclinD3, c-Myc, 
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p21waf1, and p27, angiogenesis through VEGF, and invasion and metastasis through 
MMP-2 and MMP-9 (Furqan et al., 2013; Quesnelle et al., 2007). STAT3 target genes 
also include anti-apoptotic genes such as Survivin, Mcl-1, and   Bcl-XL (Leeman et al., 
2006). There is significant overlap between the genes whose transcription is regulated 
by STAT3 and STAT5. STAT5 also mediates c-Myc, CyclinD1, CyclinD2, and Mcl-1 
transcription (Page et al., 2012). Conversely, STAT1 has not been linked to tumor 
progression but might be a tumor suppressor and activates transcription of similar 
proteins involved in cell survival (Chan et al., 2004; Ferbeyre and Moriggl, 2011; 
Watanabe et al., 2001) (Table 4). 
The oncogenic potential of STAT3 is through its control of important cell cycle 
regulators leading to cell cycle progression, survival, and malignant progression 
(Bowman et al., 2000). Figure 8 shows how STAT3 plays a role in many of the 
Hannahan and Weinberg hallmarks of cancer. STAT3 is involved in 1. Inhibiting 
apoptosis: regulation of BCL-XL and survivin, 2. Cell cycle activation: Myc, CyclinD1, 
and Cdc25A, 3. Telomere length: upregulation of telomerase, 4. Metastasis: MMP-9, 5. 
Angiogenesis: VEGF.  Many drugs have been developed to control STAT3 signaling. 
STATTIC (STAT Three Inhibitory Compound), a drug used in this project was the first 
non-peptide small molecule inhibitor for STAT3. It works by obstructing the dimerization 
of the transcription factor and therefore prevents its activity. It has been studied in a 
variety of cancers including breast, hepatocellular carcinoma, pancreatic, colon, 
glioblastoma, and multiple myeloma (Furqan et al., 2013).  
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Figure 7: STAT3 signaling pathway. 
 
	  	  	  
STAT3 is a transcription factor that can be activated by a variety of signaling cascades 
including EGFR and mTOR. This figure is reproduced with permission from Cell 
Signaling.  
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Table 4: STAT activation in tumors. 
 
 
 
 
 
 
  
Solid tumor 
type 
STAT 
activation 
Breast STAT1, STAT3, 
STAT5 
Head and neck STAT1, STAT3, 
STAT6 
Lung STAT3, STAT5 
Prostate STAT3 
Colon STAT3 
Glioma STAT3 
Melanoma STAT3 
Ovarian STAT3 
Pancreatic STAT3 
Renal STAT3 
Liver STAT3 
STATs are activated in a variety of 
solid tumors, most frequently STAT3 
and STAT5. Table reproduced with 
permission from Quesnellle et al., 
2007.  	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STAT3 is phosphorylated on two residues required for full activation, Tyr705 and 
Ser727. Of particular note, in relation to this dissertation, is that STAT3 can bind to the 
EGFR and be phosphorylated on Tyr705 through EGFR sites Y1086 and Y1068, and 
mTOR on Ser727, which increases the transcription activity (Quesnelle et al., 2007). 
One interesting article noting the crosstalk between EGFR, mTOR, and STAT3 found 
that when all three proteins are upregulated in gastric cancer, there is a significant 
correlation with higher tumor stage, lymph node involvement and invasion (Inoki et al., 
2005; Inokuchi M  et al., 2011). The combination of EGFR and mTOR inhibitors was 
found to decrease tumorigenesis in GBM cell lines through inhibition of STAT3 
phosphorylation (Rajan et al., 2003). The ability of EGFR and mTOR to converge upon 
STAT3 in different types of cancer suggests that the drug combination of EGFR and 
mTOR inhibitors should further be explored in combination for their ability to inhibit p-
STAT3.   
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Figure 8: STAT3 is involved in tumorigenesis. 
  
	  	  
STAT3 is involved in many aspects of tumorigenesis leading to a decrease in apoptosis, 
and an increase in replicative potential, metastasis, and angiogenesis. Figure is 
reproduced with permission from Barre et al., 2007.  
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CHAPTER 2: Exploring Resistance Pathways to EGFR Inhibitors 
2.1 Hypothesis and Specific Aims 
 The overall hypothesis for the project described in this dissertation is that mTOR 
inhibition can sensitize TNBC cells to EGFR TKIs through the inhibition of eIF4B and 
STAT3 phosphorylation. To test this hypothesis we addressed three specific aims:  
Aim I: To determine the effect of abrogating both EGFR and mTOR 
signaling on growth and survival in TNBC cell lines. The working hypothesis 
for this aim is that the combination of mTOR and EGFR inhibitors abrogates cell 
growth and colony formation in TNBC cells.  We tested this hypothesis by 
measuring the effect of temsirolimus and gefitinib on cell growth, colony 
formation, and viability using BT20, MDA-MB-231, and MDA-MB-468 TNBC 
cells.  We also determined the mechanism by which viability is decreased by 
measuring apoptosis, autophagy, and cytostasis.  
Aim II: To investigate the role eIF4B plays in the synergistic effect of EGFR 
and mTOR dual inhibition in TNBC cell lines. The working hypothesis for this 
aim is that the phosphorylation of eIF4B represents a common mediator of 
survival in TNBC and that this phosphorylation needs to be abrogated to 
decrease cell growth.  To test this hypothesis we used siRNA and small molecule 
inhibitors to decrease eIF4B phosphorylation and expression. We also 
investigated the role of the two kinases responsible for phosphorylating eIF4B, 
P70S6K and P90RSK. Finally, we determined the significance of cap-dependent 
versus cap-independent translation in the mediation of cell survival in TNBC cell 
lines.  
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Aim III: To identify the role of STAT3 in the treatment of TNBC cell lines 
with EGFR and mTOR inhibitors. The working hypothesis for this aim is that 
STAT3 phosphorylation is co-regulated by EGFR and mTOR signaling and that 
inhibition of STAT3 phosphorylation is required for efficacy of the combination of 
gefitinib and temsirolimus. To test this hypothesis we abrogated STAT3 
activation and phosphorylation using an established small molecule inhibitor, 
STATTC. We also constitutively activated STAT3 through plasmid transfection 
(Stat3c) to determine if STAT3 phosphorylation is a common mediator for EGFR 
and mTOR signaling.   
We think the studies proposed here outlined EGFR and mTOR inhibitors as an effective 
in vitro combination that warrants further investigation in the treatment of TNBC.  In 
addition, these studies defined the eIF4B and STAT3 signaling pathways as activated 
by EGFR and mTOR that need to be abrogated to mediate the synergistic effects of 
gefitinib and temsirolimus treatment. Clinically, many women who develop TNBC 
ultimately fail treatment and therefore better drug regiments need to be developed. 	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CHAPTER 3: Materials and Methods 
3.1 Human Breast Cancer Cell Lines and inhibitors 
Gefitinib (Iressa) was provided by AstraZeneca (London, UK). Temsirolimus was 
purchased from LC Labs (Woburn, MA, USA). STATTIC was purchased from Abcam 
(Cambridge, UK). BI-D1870 and AT7867 were purchased from Selleck Chemicals 
(Boston, MA, USA). MDA-MB-231, MDA-MB-468, and BT20 cells were purchased from 
ATCC (Manassas, VA, USA). HEK293T cells were purchased from Invitrogen 
(Carlsbad, CA, USA). MDA-MB-231, MDA-MB-468, and HEK293T cells are grown in 
DMEM+10% FBS media (Dulbecco's modified Eagle's medium supplemented with 10% 
Fetal Bovine Serum).  BT20 cells are grown in Eagle’s + NEAA  media  (Eagle's  MEM  
[Minimum Essential Medium] with 2 mM L-glutamine and Earle's Balanced Salt Solution 
adjusted to contain  1.5  g/L  sodium  bicarbonate,  0.1  mM  non-essential amino acids, 
1 mM sodium pyruvate, and 10% FBS). All other reagents were purchased from Thermo 
Fisher (Houston, TX, USA) or Sigma (St. Louis, MO, USA), unless indicated. A genomic 
profile of the cell lines with common mutations can be found in Supplemental Table 2.  
3.2 Phospho Mass Spectrometry 
The Mass Spectrometry methods were generated by Dr. Paul Stemmer and can 
be found in a recently submitted manuscript with the title “Abrogating phosphorylation of 
eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast 
cancer” of which he is a co-author with the author of this dissertation work and in 
Supplemental Methods. The samples were prepared under the guidance of Dr. 
Stemmer by J. Madden after which he took control of the samples for further analysis. 
Methods that this author performed are included.  
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BT20 cells were treated with 0.5 µM gefitinib or a DMSO vehicle control for 24 
hours. Cells were washed with ice-cold HANK’s solution then proteins precipitated with 
100% EtOH before cell proteins were scraped from plates and transferred to 
microcentrifuge tubes. Samples were then taken to the Proteomics Core and further 
analysis was performed by Dr. Paul Stemmer. Experiment was done two times with the 
first experiment containing 14 samples per treatment and the second containing 4 
samples. 
3.3. Ingenuity® Pathways Analysis 
The methods were performed by Dr. Aliccia Bollig-Fischer for a recently 
submitted manuscript with the title “Abrogating phosphorylation of eIF4B is required for 
EGFR and mTOR inhibitor synergy in triple-negative breast cancer” of which she is a 
co-author with the author of this dissertation work. As the author of this work did not do 
the bioinformatics work, detailed methods have been excluded.  
3.4 Cell Viability Assays 
Cells were plated in triplicate at 2,000 cells /well of a 96-well plate on Day 0. 
Cells were treated with 0.001 µM, 0.01 µM, 0.1 µM, 1 µM, 10 µM, 20 µM, and 50 µM 
gefitinib and/or temsirolimus, BI-D1870 and/or AT7867, and STATTIC on Day 1. The 
MTS reagent was added per manufacturer’s directions after 72 hours (Day 5) 
(Promega, Madison, WI, USA) and was read using a Dynex spectrophotometer. 
GraphPad Prism was used to generate GI50 curves at inhibitory growth curves with 
top=1 and bottom=0. GI50 values were generated by the program from the data of at 
least three experiments performed in triplicate.  
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3.5 Cell Growth Analysis 
Cells were plated in triplicate at 30,000/ well of a 6 well plate on Day 0. 
Treatment with gefitinib (1 µM), temsirolimus (1 µM), BI-D1870 (10 µM), AT7867 (10 
µM), alone or in the combinations specified in the text began on Day 1 and continued 
every other day for 8 days.  Day 1 untreated cells were counted using a 
hemocytometer. On Days 4 and 8 the respective plates were counted again using a 
hemocytometer. Experiments were repeated at least three times. Graphs were prepared 
and statistical analysis was performed in GraphPad Prism (La Jolla, CA, USA) using an 
ANOVA.  
3.6 Clonogenic Survival Assays 
BT20 cells (40,000 cells/ 35-mm dish) or MDA-MB-231 and MDA-MB-468 cells 
(30,000 cells/ 35-mm dish) were plated on Day 0. Cells were treated with gefitinib ([1 
µM BT20] [10 µM MDA-MB-231 and MDA-MB-468]) and/or temsirolimus ([1 µM BT20] 
[10 µM MDA-MB-231 and MDA-MB-468]) as specified in the text. Treatment began on 
Day 1 and continued every other day for 10 days. On day 10, cells were trypsinized and 
replated at 5,000 cells/ 35-mm dish (BT20) or 3,000 cells/ 35-mm dish (MDA-MB-231 
and MDA-MB-468) without treatment for 7 days. Different plating densities allowed for 
the longer doubling time in BT20s compared to MDA-MB-231 and MDA-MB-468, which 
replicate more quickly. Colonies were stained with crystal violet for 20 minutes, washed 
with water to remove excess dye, and counted using the Gelcount colony counter the 
following day (Oxford Optromix; Abingdon, United Kingdom). Counts were normalized to 
the untreated control for each experiment. Experiments were done in triplicate and 
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repeated at least three times. Graphs were prepared and statistical analysis was 
performed in GraphPad Prism using an ANOVA. 
3.7 Immunoblotting 
Cells were lysed in CHAPS lysis buffer (10 mM CHAPS, 50 mM Tris [pH 8.0], 
150 mM NaCl, and 2 mM EDTA with 10 µM Na3VO4 and 1x protease inhibitor cocktail 
[EMD Biosciences, Rockland, MA]) at 4°C. Proteins were separated using sodium 
dodecyl sulfate (SDS)–polyacrylamide gel electrophoresis (PAGE) 7.5% or 12% gel and 
transferred onto polyvinylidene fluoride (PVDF) membranes for 1 hour at 23V. Blots 
were blocked in 5% milk or 5% BSA according to manufacturer’s instructions and then 
were placed in primary antibody overnight at 4°C shaking, washed with TBS-T for 10 
minutes x3, and incubated with secondary antibody for 1 hour at room temperature. 
After secondary antibody incubation, blots were washed with TBS-T for 10 minutes x3 
and developed using Amersham ECL Prime Western Blotting Detection Reagent 
solution (GE Healthcare, Amersham, United Kingdom). Relevant antibodies can be 
found in Table 4. Antibodies used in this study were purchased from Cell Signaling 
Technologies (Beverly, MA, USA), BioSouce (Grand Island, NY, USA), or Millipore 
(Billerica, MA, USA).  
3.8 siRNA silencing 
 siRNA constructs were purchased from Thermo Scientific Dharmacon®. 
Constructs to eIF4B are non-overlapping and described as #7 (catalog number J-
020179-07 sequence 5’ AAACCUACCCUAUGAUGUU 3’) and #8 (catalog number J-
020179-08 sequence 5’ GCAGUGCGUUUACCACGUG 3’) in the text. Non-silencing off-
target siRNA (non-silen) was used as a control (catalog number D-0018810-01-05). 
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Plates were treated with 0.7 µg/ well siRNA (96 well) or 2.5 µg siRNA / well (6 well) 
siRNA using the Lipofectamine LTX transfection system. siRNA was combined with  
Lipofectamine LTX and PLUS in Opti-MEM supplemented with antibiotic free growth 
media to  a final volume (96 well LTX  0.3 µL, PLUS 0.01 µL, 6 well LTX 2 µL, PLUS 0.5 
µL).  
3.9 Bicistronic luciferase Assay 
A dual luciferase plasmid was purchased from Addgene (Cambridge, MA, USA). 
HEK293T cells were transfected with 11510:pFR_HCV_xb (Supplemental Figure 2). 
After 24 hours, media were removed and replaced with media containing gefitinib and/or 
temsirolimus at 1 µM. Cells were then harvested after an additional 24 hours and 
luciferase activity was measured using the Dual-Luciferase Reporter Assay System 
(Promega, Madison, WI, USA) and read using the BioTek Synergy 2 machine 
(Winooski, VT, USA) according to the manufacturer’s instructions. Relative luciferase 
units were plotted in GraphPad Prism as normalized firefly (cap-dependent translation) 
over normalized renilla (cap-independent translation).  
3.10 Stat3c plasmid 
 The EF.STAT3C.Ubc.GFP plasmid (Stat3c) to express constitutively activated 
STAT3 was purchased from Addgene, plasmid number 24983 (Hillion et al., 2008). 
Cells were treated with 1 µg/well plasmid DNA (96 well) or 1.5 µg DNA/well (6 well) 
using the Lipofectamine LTX transfection system. Stat3c was combined with 
Lipofectamine LTX and PLUS in Opti-MEM supplemented with antibiotic free growth 
media to final volume (96 well LTX  0.3 µL, PLUS 0.08 µL, 6 well LTX 3 µL, PLUS 1 µL) 
and harvested or read through MTT cell viability assay after 72 hours.  
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3.11 STAT3 DNA Binding ELISA 
 The STAT3 Transcription Factor Assay Kit (catalog number 45696) was 
purchased from Active Motif (Carlsbad, CA, USA). Protocol was followed according to 
manufacturer’s instructions. Briefly, the kit detects and quantifies the transcription factor 
activity when active STAT3 in the sample binds to a STAT3 consensus sequence that is 
bound to the kit plate (5’ TTCCCGGAA 3’). A STAT3 primary antibody detects the 
STAT3 bound to the plate containing the STAT3 consensus site and a secondary HRP-
conjugated antibody provides a colormetric readout that is then quantified using 
spectrophotometry. 10 µg of cell lysate was used for each assay. Experiments were 
repeated at least two times. Treatments were 1 µM of the indicated drug for 24 hours.  
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Table 5: Relevant antibody information.  	  
Target Company Catalog number Dilution used 
AKT Cell Signaling 9272 1:1000 
Caspase 3 Cell Signaling 9665 1:1000 
Caspase 7 Cell Signaling 9494 1:1000 
Caspase 9 Cell Signaling 9508 1:1000 
Cleaved Caspase 3 Cell Signaling 9501 1:1000 
Cleaved Caspase 7 Cell Signaling 9491 1:1000 
Cleaved Caspase 9 Cell Signaling 9664 1:1000 
EGFR Cell Signaling 2232 1:1000 
eIF4A Cell Signaling 2013 1:1000 
eIF4A1 Cell Signaling 2490 1:1000 
eIF4B Cell Signaling 3592 1:1000 
eIF4E Cell Signaling 2067 1:1000 
eIF4G Cell Signaling 2469 1:1000 
eIF4H Cell Signaling 2444 1:1000 
Anti-mouse IgG HRP linked Cell Signaling 7076 1:1000 
Anti-rabbit IgG HRP linked Cell Signaling 7074 1:2000 
LC3* Cell Signaling 4599 1:1000 
MAPK Cell Signaling 9102 1:1000 
P21Waf1* Cell Signaling 2946 1:2000 
P38 Cell Signaling 9212 1:1000 
P53 Millipore OP09 1:1000 
P70S6K Cell Signaling 2708 1:2000 
phospho-AKT (Ser473) Cell Signaling 4060 1:2500 
phospho-EGFR (Thr669) Cell Signaling 3056 1:1000 
phospho-EGFR (Tyr1045) Cell Signaling 2237 1:500 
phospho-EGFR (Tyr1068) Cell Signaling 2234 1:5000 
phospho-EGFR (Tyr1086) Cell Signaling 2220 1:500 
phospho-EGFR (Tyr1173) Cell Signaling 4407 1:500 
phospho-EGFR (Tyr845) Cell Signaling 2231 1:750 
phospho-EGFR (Tyr992) Cell Signaling 2235 1:500 
phospho-eIF4E (Ser209) Cell Signaling 9741 1:1000 
phospho-eIF4G (Ser1108) Cell Signaling 2441 1:2000 
phospho-MAPK (Thr20/Try204) BioSource 44-680g 1:2000 
phospho-P38 (Thr180/Tyr182) Cell Signaling 9211 1:500 
phospho-P70S6K (Thr389) Cell Signaling 9205 1:1000 
phospho-P90RSK (Ser380) Cell Signaling 9335 1:500 
phospho-PKCpan Cell Signaling 9371 1:1000 
phospho-STAT3 (Y705)* Cell Signaling 9138 1:500 
phospho-STAT3 (S727) Cell Signaling 9134 1:1000 
RSK1/2/3 Cell Signaling 9355 1:500 
β-actin* Sigma A5441 1:10000 
 
 
    
Antibodies used in this work were purchased from Cell Signaling, BioSource, or 
Millipore. Catalog numbers and concentrations used are provided. All antibodies are 
used with secondary rabbit HRP-linked IgG unless noted with * indicating use of mouse 
HRP-linked IgG. 
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CHAPTER 4: Identification of proteins remaining phosphorylated after gefitinib 
treatment in TNBC 
4.1 Introduction 
As previously mentioned 50% of TNBC patient tumors express high levels of 
EGFR but are resistant to inhibitors (Liu et al., 2011). EGFR inhibitors are approved in 
the clinic for colon and NSCLC but have proven ineffective for breast cancer due to high 
levels of developed and de novo resistance. Therefore, they are not used as a single 
agent therapy but are given in combination with cytotoxics (Chong and Janne, 2013). 
An emerging technology is the use of proteomics to better understand complex 
signaling networks within the cell.  The therapeutic potential of phospho-proteomics is 
rapidly advancing (Lopez et al., 2012). Since many signaling proteins are considered 
active based on the presence or absence of a phosphate(s) group (PO43-), phospho-
proteomics is an excellent tool to study protein activation on a massive scale. 
Interpreting the data through bioinformatics can then allow for identification of important 
signaling pathways specific for the samples. Other phospho techniques, such as 
antibody detection of protein levels through immunoblotting are limited in their ability to 
identify only one protein at a time, but phospho-mass spectrometry is able to detect and 
measure the phosphorylation of tens of thousands of proteins simultaneously. Mass 
spectrometry based assays can assist in drug development through (i) clarification of 
the mechanism of drug action, (ii) identification of proteins related to a signaling 
network, (iii) discovering novel drug targets for diseases (Lopez et al., 2012; Lopez et 
al., 2011). While phospho-proteomics can be a good tool to identify drug targets, it also 
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has promise to be used on a patient level to diagnose and better understand the 
individual disease and help predict treatment response (Lopez et al., 2012).  
Phospho-mass spectrometry is able to capture and identify proteins based on the 
presence of the phosphate group. Once proteins have been precipitated in ethanol, they 
are digested, run through a titanium dioxide (TiO2) column to select for peptides 
containing a phosphate. TiO2 was used as the selecting agent in this work as it is able 
to select proteins phosphorylated at serine, tyrosine, and threonine sites, therefore, 
giving a complete profile of the phospho-proteome (Chen and Chen, 2005). The 
phosphorylated proteins are then identified through mass-spectrometry.  
4.2 Results 
4.2.1 Summary of proteins remaining phosphorylated in the presence of gefitinib 
In order to identify potential mechanisms of resistance to EGFR inhibitors in 
TNBC, we utilized a phospho-proteomics approach. We treated the TNBC cell line, 
BT20 with gefitinib, an EGFR TKI and performed Phospho Mass Spectrometry with the 
help of the Proteomics Core at Wayne State and Dr. Paul Stemmer. BT20s were 
chosen for their TNBC status, high levels of EGFR, and intrinsic resistance to EGFR 
TKIs. Briefly, after 24 hours treatment with gefitinib or a vehicle treated DMSO control, 
proteins were harvested in ethanol. The samples were then sent to the Proteomics Core 
where they were lysed in deoxycholate and digested in trypsin. The phospho-peptides 
were enriched at all three phosphosites, tyrosine, serine, and threonine using TiO2. The 
Proteomics Core was able to identify 279 proteins whose phosphorylation statues did 
not significantly change in the presence of gefitinib. All identified proteins can be found 
in Supplemental Table 1.  
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4.2.2 mTOR signaling remains activated in the presence of EGFR inhibitors in 
TNBC 
With the help of the Bioinformatics Core and Dr. Aliccia Bolig-Fischer we utilized 
Ingenuity® Pathway Analysis to interpret the phospho-proteomic data.  Bioinformatics 
are a useful tool to identify commonalities within a data set and have been used in many 
studies to discover relevant signaling pathways from a library of proteins. The analysis 
found many pathways containing multiple proteins that remained activated after gefitinib 
treatment. The top scored pathways are found in Table 6. Molecular transport, RNA 
trafficking, and protein synthesis had the highest number of associated proteins. This 
analysis also led us to discover many of the phosphorylated proteins from the proteomic 
data are involved in the mTOR pathway, particularly translation initiation (Table 7). 
4.3 Conclusions 
mTOR is often activated in many types of cancer and has been studied in 
relation to resistance to EGFR inhibitors (Buck et al., 2006; Wheeler et al., 2008). EGFR 
and mTOR pathways have been implicated in cancer progression and linked as having 
extensive crosstalk for many years (La Monica et al., 2009; Rini et al., 2007). Therefore, 
the bioinformatics data led us to further explore the role of mTOR as a mechanism of 
resistance in TNBC due to the high number of mTOR related proteins that remained 
activated after EGFR inhibition.  
Of note many proteins remained phosphorylated after gefitinib treatment in the 
Mass Spec data as seen in the Supplemental Table 1. Many of these proteins fit into a 
variety of pathways that we could have explored as mechanisms of resistance for this 
project. mTOR is only one of what can be many other pathways that contribute to EGFR 
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inhibitor resistance in TNBC. Many of the pathways related to mTOR had the top hits in 
the proteomics data. eIF2, eIF4, and P70S6K had the most number of proteins involved 
that fit into the pathway. However, other pathways were also enriched in high numbers 
including Integrin signaling, RhoA, and CHK mediated cell cycle control. Phospho-
proteomics are a good resource to identify pathways that can contribute to inhibitor 
resistance and generate hypothesis driven research. It is a tool that can lead to 
interesting pathways and proteins that otherwise would have remained undiscovered.   
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Table 6: Ingenuity® Pathway Analysis Top Functional Scores. 
 
Score Focus Molecules Top Functions 
54 27 Molecular Transport, RNA Trafficking, Protein Synthesis 
44 23 
Cardiovascular System Development and Function, 
Organismal Development, Cellular Assembly and 
Organization 
41 22 Cell Cycle, DNA Replication, Recombination, and Repair, Gene Expression 
39 21 Cellular Compromise, Cellular Function and Maintenance, Protein Synthesis 
23 15 Infection Mechanism, Reproductive System Disease, Cellular Assembly and Organization 
23 14 
Cellular Assembly and Organization, Cellular Function 
and Maintenance, Nervous System Development and 
Function 
17 11 
Cellular Development, Hematological System 
Development and Function, Connective Tissue 
Development and Function 
15 10 Cellular Compromise, Cellular Growth and Proliferation, Cellular Assembly and Organization 
 
 
Ingenuity based pathway analysis sorted proteins based on the phospho-proteomic data 
and scored the most commonly activated pathways. Analysis is based on proteomic 
data from BT20 cells treated with 0.5 µM gefitinib compared to a DMSO vehicle control. 
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Table 7: Proteins involved in translational control that remained phosphorylated 
after gefitinib treatment involved in mTOR pathway.  
 
Cells were harvested in ice cold ethanol, lysed in deoxycholate, trypsin digested, and 
phospho-peptides were enriched at tyrosine, serine, and threonine sites using Ti2O. 
Phospho-mass spectrometry on BT20 cells showed 279 proteins remained activated in 
the presence of 0.5 µM gefitinib. Ingenuity® based pathway analysis found many 
components of the mTOR pathway and translation initiation factors to be of interest. A 
complete list of phosphorylated proteins can be found in Supplemental Table 1.   
Proteins involved in translational control that remained phosphorylated after 
gefitinib treatment involved in mTOR pathway 
Protein Function in Translation  
eIF1B Enhance rate and accuracy of Translation  
eIF3B Step 1 of Translation initiation 40S subunit binding 
eIF3D Step 1 of Translation initiation 40S subunit binding 
eIF3G Step 1 of Translation initiation 40S subunit binding 
eIF3J Step 1 of Translation initiation 40S subunit binding 
eIF3C Step 1 of Translation initiation 40S subunit binding 
eIF2A Step 2 Bind initiator tRNA and 40S subunit 
eIF4G1 Step 3 of Translation initiation activation and binding of mRNA to 40S  
Raptor Major subunit of mTORC1 
Rictor Major subunit of mTORC2 
GSK3A  Glycogen synthase kinase  
4EBP1 Directly binds and activates eIF4E- rate limiting step in Translation initiation 
FKHR 
(FOXO3) 
Forkhead Transcription factor- glucose homeostasis, cell-cycle 
progression, and apoptosis 
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CHAPTER 5: EGFR and mTOR Inhibitor Synergy in TNBC 
5.1 Introduction 
TNBC cells with high levels of EGFR have an intrinsic resistance to EGFR TKIs. 
Phospho-proteomic data indicated that the mTOR pathway may be responsible for 
EGFR inhibitor resistance and suggest that inhibition of mTOR may circumvent this 
resistance and sensitize cells to EGFR treatment. Rapamycin (sirolimus) was first 
discovered in the soil of Easter Island as a macrolide antibiotic produced from 
Streptomyces hygroscopicus and was used as an immune suppressant after patients 
received organ transplants (Albert et al., 2010; Vezina et al., 1975). Analogs of the drug 
have been developed, coined rapalogs, also inhibit mTOR.  
5.2 Results 
5.2.1 Inhibiting mTOR activity sensitizes TNBC cells to EGFR Inhibitors 
In our studies we have chosen to use the mTOR inhibitor temsirolimus, which is 
used in the clinic to treat renal cell carcinoma (Albert et al., 2010). MTT assays were 
used to determine the GI50s of temsirolimus for the TNBC cell lines. The cell lines used 
in this project were chosen due to their triple negative status, the fact that they contain 
high levels of EGFR, and have an increased resistance to EGFR inhibitors (µM GI50 
values, Table 8). As seen in Table 8, the temsirolimus GI50 values for the BT20, MDA-
MB-231, and MDA-MB-468 TNBC cell lines were all >9.5 µM, a value considered to 
indicate resistance to mTOR inhibition.  
We further used growth assays to determine the effect gefitinib and temsirolimus 
had individually and in combination on TNBC cells. Cells were plated on Day 0, treated 
on Day 1, and every other day until Day 8, with gefitinib, temsirolimus, or the 
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combination at the indicated doses (Figure 9A).  On Days 1, 4, and 8, cells were 
counted using a hemocytometer from triplicate wells and plotted using GraphPad Prism.  
In support of the MTT GI50 data in Table 8, gefitinib (GEF) and temsirolimus (TEM) did 
not have a significant effect on cell growth in any of the cell lines (Figure 9A, red and 
green lines). However, the 1:1 combination of gefitinib and temsirolimus at 1 µM had a 
significant decrease (p<0.01 for MDA-MB-231, and p<0.001 for BT20 and MDA-MB-
468) in cell growth over an 8 day period that was not seen with single agent treatment at 
the same concentration in all cell lines (Figure 9A). There was also a significant 
decrease in growth comparing GEF (red line) and GEF+TEM combination (blue line) in 
all cell lines (p<0.05). EGFR and mTOR dual inhibition has a significant effect at 
decreasing TNBC cell growth that is not observed with individual treatment. Both 
gefitinib and temsirolimus are approved for the treatment of cancers. Using already 
approved drugs in a new setting allows for easier study and transition into patients, as 
the toxicity profile is known. FDA approval for drugs already in the clinic is much easier 
if they show efficacy in a new disease. Therefore, it is a significant finding that our 
studies found a synergistic effect at decreasing TNBC cell growth using approved 
drugs.  
Clonogenic survival assays were then utilized to analyze the ability of EGFR and 
mTOR inhibitors to decrease cell survival over an extended period of time. The assay is 
a way to look at resistance as the cells are grown with drug treatment for a 10 days, 
replated and grown with normal growth media for another week to see if they were able 
to recover from the drug treatment. An effective cancer treatment needs to efficiently 
and permanently inhibit cell growth while circumventing resistance, a major problem for 
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TNBC patients in the clinic. While single agent treatment with gefitinib and temsirolimus 
had minimal effects at decreasing colony formation, the combination showed a 
significant decrease (Figure 9B p*<0.05, **0.01, ***0.001, ****0.0001). One cell line, 
BT20, had a significant decrease in colony formation when treated with single agent 
temsirolimus treatment. Our results suggest that mTOR inhibition has a greater effect at 
decreasing cell growth and colony formation than single agent EGFR inhibition but not 
to the extent of the combination.  Our data suggest that mTOR inhibition can sensitize 
TNBC cells that are resistant to EGFR inhibitors and decrease cell growth and colony 
formation.  
5.2.2 EGFR and mTOR inhibitors are synergistic in TNBC 
Other studies have found that EGFR and mTOR inhibitors in combination are 
effective experimentally in NSCLC, pancreatic, colon and breast cancers (Buck et al., 
2006; Chacon and Costanzo, 2010).  Our results demonstrate a significant decrease in 
growth and colony formation with the combination treatment of gefitinib and 
temsirolimus (Figure 9). As mentioned previously, MTT data on three TNBC cell lines 
shows that they are resistant to single agent treatment of gefitinib and temsirolimus 
(Table 8). The growth and colony assays suggest a combinatorial effect. Figure 10A 
shows GI50 growth curves for all cell lines. The combination of gefitinib and temsirolimus 
(GEF+TEM) shifts the curves to the left, indicating a lower GI50 value than with the 
individual treatments alone. The raw MTT data were then used to evaluate the synergy 
of the two drug combination using the Chou-Talalay method (Chou, 2006).  
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Table 8: Gefitinib and temsirolimus GI50 and CI values in TNBC.  
 
Cell Line GI50 GEF GI50 TEM 
GI50 
GEF+TEM 
CI 
value 
BT20 5.3 µM 9.79 µM 0.94 µM 0.21 
MDA-MB-231 >100 µM >100 µM 4.1 µM 0.28 
MDA-MB-468 6.8 µM 16.4 µM 3.7 µM 0.56 
 
  
The GI50 values for each TNBC cell line were considered resistant for individual drug 
treatments. The combinations had lower GI50 values for all cell lines and the CI values 
were calculated using CalcuSyn. All CI values <1.0 indicate a synergistic effect with the 
combination of gefitinib and temsirolimus in BT20, MDA-MB-231, and MDA-MB-468 
cell lines.  	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Using CalcuSyn software we calculated the GI50 value for each cell line and drug 
from MTT assays done with increasing concentrations of gefitinib and temsirolimus at 
constant ratios. The GI50 for each individual drug alone is plotted on a graph, gefitinib on 
the Y-axis and temsirolimus on the X-axis (Figure 10B). By drawing a line between the 
GI50 values and plotting the calculated drug concentration in the presence of the other 
drug on the same graph (Figure 10B, triangles) for a given drug concentration, we can 
observe synergy. Any points falling under the line indicate the drug combination is 
synergistic. In all three cell lines, all points fall below the line indicating synergy. The 
calculation of CI (combinatorial index) values was done to further confirm the synergy of 
gefitinib and temsirolimus in TNBC cell lines (Table 8). CI values less than 1.0 are 
another indicator of synergy and all cell lines had calculated CI values of less than 1.0. 
Together, our data confirm what others have seen and suggest that EGFR and mTOR 
inhibition results in a significant and synergistic decrease in cell growth and colony 
formation in TNBC cell lines. 
5.2.3 Cell death mechanism 
 The synergy observed with the gefitinib and temsirolimus combination along with 
the decreases in growth and colony formation suggest changes in TNBC cell line 
survival, viability, and proliferation. In order to further understand how the treatment 
combination has led to the observed effects we explored cell death mechanisms to 
understand these decreases and synergy. Many cancer therapeutics decrease cancer 
cell growth by initiating apoptosis or cell suicide when the genetic material becomes 
damaged enough to trigger death. When apoptosis is initiated, pro-caspases are 
cleaved to their activated state and start the cascade leading to cell death.   
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Figure 9: Gefitinib and temsirolimus combination decreases TNBC cell growth 
and colony formation.  
 
 
 
A. Cell growth assays were done on BT20, MDA-MB-231, and MDA-MB-468 cells over 
8 days in triplicate. Cells were treated every other day with 1 µM and counted on days 
1,4, and 8 with a  hemacytometer. ANOVAs were performed on GraphPad Prism 
software with a significant decrease with the combination of gefitinib and temsirolimus 
(GEF+TEM 1 µM) in all three cell lines. B. Colony formation assays were plated in a 6 
well plate in triplicate. Treatments were done every other day at 1 µM for two weeks in 
BT20 cells and 10 µM in MDA-MB-231 and MDA-MB-468. Cells were trypsinized, 
replated at a low density, and allowed to grow for another week in normal growth media. 
Colonies were counted on a Cell Counter. ANOVAs were done in GraphPad Prism 
software and found a significant decrease in colony formation in the gefitinib and 
temsirolimus (GEF+TEM) combination (blue bars). p*<0.05 **<0.01 ***0.001 ****0.0001 
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Cleaved caspases are therefore a good marker for induction of apoptosis, along with 
cleavage of another late stage apoptosis associated protein, PARP. We used 
immunoblotting to look at three cleaved caspases 3, 7, and 9 and cleaved PARP as 
indicators of apoptosis (Figure 11). There was no increase in apoptotic markers 
observed in the MDA-MB-231 or MDA-MB-468 cells after 72 hour of treatment.  
Treatment time courses from 0 to 72 hour were performed to ensure markers of 
apoptosis were not missed in these studies.  
mTOR is known to play a role in autophagy, another mechanism of cell death 
(Laplante and Sabatini, 2009). mTOR controls autophagy in times of cell stress and can 
initiate the recycling of cellular components when nutrients are scarce or in response to 
certain chemotherapy drugs (Albert et al., 2010). A marker for autophagy is the 
observance of increased compartments within the cell called autophagosomes that can 
be observed under the microscope and the increased levels of converted LC3. After 
treatment with the inhibitors, there appeared to be no increase in autophagosome 
formation across the treatments (observed data not shown). Further immunoblotting 
shows no increase in LC3 conversion suggesting that autophagy plays a minimal role in 
the observed synergy (Figure 11).  
The data suggest only a decrease in cell growth and colony formation, not a 
complete inhibition (Figure 9). The growth curves slow over time (8 day time point) 
suggesting a potential role for a cytostatic effect of gefitinib and temsirolimus 
combination. Cytostasis is the process by which cells are removed from the cell cycle 
therefore they are unable to proliferate. Cellular markers of cytostasis include the 
accumulation in p21 and p53, two proteins that, when increased, stop progression of the 
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cell cycle. Interestingly, there was an increase in both proteins with the combination 
treatment. p53 levels increase after 24 hours while p21 levels take 48 hours to increase, 
as shown through immunoblotting (Figure 11). Our results are in agreement with other 
studies that have found the combination of EGFR and mTOR inhibitors is cytostatic 
(Boffa et al., 2004; La Monica et al., 2009). 
5.3 Conclusions 
The phospho-proteomic data suggest a role for the mTOR pathway in EGFR 
inhibitor resistance in TNBC cell lines. The data also propose that TNBC cell lines are  
resistant to single agent mTOR inhibition (Albert et al., 2010; Buck et al., 2006). Further, 
MTT viability found that the combination of EGFR and mTOR inhibitors was synergistic 
and significantly decreased cell growth and colony formation compared to single agent 
treatment. The lack of activation of caspases and PARP cleavage suggests a minimal 
role of apoptosis and a lack of LC3 conversion supports a minimal role for autophagy as 
being a mechanism of the observed decrease in cell growth and colony formation. 
However, the data suggest the cells are undergoing cytostasis and stalling their growth 
instead of triggering cell death. Further, the addition of an mTOR inhibitor can sensitize 
TNBC cell lines to EGFR inhibitor treatment and needs to be further explored in EGFR 
overexpressing TNBC as a treatment option. As the effect appears to be cytostatic, the 
addition of a cytostatic drug along with EGFR and mTOR inhibition also needs to be 
explored as a treatment option. While these results confirm what others have seen with 
the combination of an EGFR and mTOR inhibitor in cancer cell lines, the mechanism of 
action is still unknown, which we wanted to further explore. 
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Figure 10: Gefitinib and temsirolimus synergize in TNBC cells. 
	  
	  	  
A. The GI50 curve for BT20 cells was plotted in the presence of gefitinib (GEF), 
temsirolimus (TEM) or the combination (GEF+TEM). The combination treatment 
decreases the GI50 for the three cell lines (blue lines compared to red or green). 
Calculations done in CalcuSyn B. Isobolograms were made by plotting the GI50 of GEF 
on the Y axis and TEM on the X axis. Points falling below the drawn line indicate a 
synergistic effect of the drug combination at a constant ratio.  
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Figure 11: Cell death and senescence in gefitinib and temsirolimus treated TNBC. 
 
 
 
	  	  
 
 
After 72 hour 1 µM treatment of gefitinib (GEF) and/or temsirolimus (TEM) in MDA-MB-
231 and MDA-MB-468 cells, there is no increase in cleavage of common apoptosis 
proteins including Caspases 3, 7, 9, and PARP. Autophagy associated protein LC3 also 
has minimal fluctuation after 72 hours indicating apoptosis and autophagy do not play a 
major role in the reduction of TNBC viability, cell growth, and colony formation. 
Increased p21 and p53 are markers for cytostasis. MDA-MB-231 and MDA-MB-468 
cells have increased p21 and p53 after 1 µM treatment with GEF+TEM after 24 and 48 
hours.  
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CHAPTER 6:  Signaling in the presence of EGFR and mTOR inhibitors 
6.1 Introduction 
After observing the synergy and significant decrease in growth and colony 
formation from the combination of gefitinib and temsirolimus, we sought to find the 
protein(s) that are responsible for regulating the observed effects. The EGFR has many 
sites that can be phosphorylated to induce growth signaling and stress response 
pathways, and sites that, when phosphorylated induce receptor internalization. While 
the TNBC cells are resistant to EGFR inhibitor treatment, they still respond to EGFR 
inhibitors through receptor dephosphorylation but not at all sites. This 
dephosphorylation is a good indicator of drug potency and brings up the question of 
signaling crosstalk within the cell since, even though the receptor itself no longer 
contains the signaling phosphate, downstream effector proteins are still activated. While 
a detailed analysis of the different phosphorylation sites on the EGFR and their 
signaling output is beyond the scope of this work, an excellent review on the subject 
was written by Jorissen et al., 2002. A diagram of EGFR sites and their signaling 
effector molecules can be seen in Figure 3.  
6.2 Results 
6.2.1 EGFR remains phosphorylated in the presence of gefitinib and temsirolimus 
Immunoblot analysis on BT20 cells showed that many of the common 
phosphorylation sites on the EGFR are dephosphorylated when treated with gefitinib (1 
µM [Figure 12]). While some sites are dephosphorylated, known downstream proteins 
may still be activated by other mechanisms e.g., Y1068 and MAPK (Figure 12, row 6).  
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Figure 12: EGFR phosphorylation sites after EGFR and mTOR inhibitor treatment.  	  	  
	  
 
 
Treatment with gefitinib is able to abrogate EGFR phosphorylation on many sites. 
Resistance to gefitinib in BT20 cells has allowed for alternate activation of effector 
proteins even when the phosphorylation site is inhibited (Row 6 Y1068 and MAPK). 
Gefitinib is unable to dephosphorylate Y992 and there is subsequent activation of the 
corresponding effector protein PKC (row 4). Cells were treated with 1 µM gefitinib 
and/or temsirolimus for 24 hours, whole cell lysates were separated on a SDS-PAGE 
gel.  
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It is of note that total EGFR levels decrease when treated with GEF+TEM suggesting 
the combination is able to stimulate internalization of the receptor, possibly in a manner 
similar to EGFR antibodies. When an EGFR antibody (e.g., cetuximab, panitumumab) 
binds the receptor, it triggers a conformational change, which often leads to receptor 
internalization. This makes the action of the drug two fold, it inhibits the ability of the 
receptor to phosphorylate downstream effector proteins, and it promotes internalization 
leading to decreased EGFR levels on the cell membrane able to bind growth factor 
signals. 
6.2.2 Activation of MAPK signaling pathways in the presence of temsirolimus and 
gefitinib    
 We further performed immunoblot analysis on BT20, MDA-MB-231, and MDA-
MB-468 cell lines to determine if classical proteins involved in EGFR and mTOR 
signaling were affected by dual inhibition of EGFR and mTOR (Figure 13).  Specifically, 
phosphorylation of MAPK, p38MAPK, and AKT along with total protein controls were 
blotted for after 24 hour treatment with gefitinib and/or temsirolimus. EGFR classical 
pathway activation is through the Ras-Raf-MEK-MAPK cascade or stress signaling 
through p38MAPK. mTOR is part of the AKT/PI3K pathway. Unexpectedly, MAPK and 
p38MAPK phosphorylation was not changed with the single or combination treatments 
(Figure 13, rows 1 and 3). In contrast, p-AKT increased with temsirolimus treatment in 
BT20 cells while remaining fairly constant in MDA-MB-231 and MDA-MB-468 while 
gefitinib had no effect compared to untreated (Figure 13, row 5). mTOR inhibitors are 
known to be ineffective as single agents as AKT has an activating feedback loop when 
mTOR is inhibited as seen in BT20s (Hennessy et al., 2005; Wang et al., 2008). Our 
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results show that, taken together, the classical pathways involved in EGFR and mTOR 
signaling remain activated with gefitinib and temsirolimus treatment and are likely not 
involved in the synergy we observe with the combination in TNBC cell lines. 
6.3 Conclusions 
 Both the EGFR and mTOR pathways are linked with signaling cascades that can 
lead to tumorigenesis. Our results indicate that the most commonly associated 
pathways linked with EGFR and mTOR remain activated with gefitinib and temsirolimus 
combination treatment suggesting they are not responsible for the observed synergy. 
Our data indicate that MAPK, p38, and AKT are not the major players that are inhibited 
with treatment leading to the decrease in growth and colony formation and further 
experiments need to be done to elucidate the proteins responsible for the observed 
synergy.   
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Figure 13: MAPK and AKT signaling remain activated in the presence of EGFR 
and mTOR inhibitors.	  
	  
	  
	  
 
 
Immunoblot analysis of TNBC cell lines. Cells were treated with 1 µM GEF and/or 
TEM for 24 hours. Lysates were electrophoresed on a SDS-PAGE gel and 
transferred to a PDVF membrane. There is minimal change in phosphorylation 
across all treatments in TNBC cell lines with the main signaling proteins associated 
with EGFR and mTOR signaling, MAPK, p38, and AKT, respectively. No decrease in 
phosphorylation with the combination of GEF+TEM suggests a minimal role for 
these proteins in regulating the observed synergy.  	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CHAPTER 7: Role of eIF4B 
7.1 Introduction 
 The common signaling proteins involved in EGFR and mTOR signaling did not 
offer an explanation for the synergy we observe with gefitinib and temsirolimus dual 
treatment. Upon returning to the phospho-proteomic data, it was seen that many of the 
proteins that remained activated are involved in translation. mTOR controls translation 
initiation through downstream effector proteins P70S6K and 4E-BP1. Translation is 
often overactive in cancer and while it is usually a highly controlled process, when 
mTOR is misregulated as often happens in cancer, oncogenic proteins are translated at 
a greater rate leading to increased carcinogenesis (Loreni et al., 2013; Silvera et al., 
2010).  
Upon activation, mTOR phosphorylates two effector proteins involved in 
translation, P70S6K and 4E-BP1 (Raught et al., 2004; van Gorp et al., 2009). P70S6K 
as described above, controls the phosphorylation of initiation factor eIF4B and 4E-BP1. 
The latter sequesters eIF4E rendering it inactive. eIF4B facilitates eIF4A helicase 
activity while eIF4E is the rate limiting factor in formation of the cap-binding complex, 
eIF4F (Raught et al., 2004; Roux et al., 2007; Silvera et al., 2010). Translation begins 
when the 40S ribosome binds the newly formed eIF4F complex containing eIF4E, 
eIF4G, and eIF4A (Gingras et al., 1999; Merrick, 2004). When eIF4B is phosphorylated 
it makes the helicase activity of eIF4A more efficient (Gingras et al., 1999; Shahbazian 
et al., 2010a). 
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7.2 Results 
7.2.1 eIF4B phosphorylation is lost with the combination of temsirolimus and 
gefitinib in TNBC 
We analyzed the expression and phosphorylation of a number of translation 
initiation proteins (Figure 14). Immunoblotting of the eIF4 family showed no change in 
protein expression across the treatments.  However, eIF4B phosphorylation was 
completely abrogated with the combination gefitinib and temsirolimus while remaining 
unchanged with single agent treatment consistently in each of the three cell lines 
(Figure 14, row 1). These data suggest that inhibition of both EGFR and mTOR 
signaling is required to abrogate eIF4B phosphorylation in the TNBC cell lines we 
tested. 
7.2.2 Decrease in eIF4B expression decreases cell viability in TNBC 
We further measured cell viability when eIF4B is knocked down through siRNA 
constructs. As there currently is no available eIF4B specific inhibitor, using siRNA 
allowed us to directly target the translation initiation factor and compare knockdown to 
EGFR and mTOR inhibitor treatment. Cell viability as measured through MTT showed a 
similar drop in viability with GEF+TEM treatment compared to eIF4B knockdown in 
MDA-MB-231 cells (Figure 15). There is a significant decrease between the #8 eIF4B 
knockdown construct and NT, and #8 and a nonsilencing control. It is important to note 
that #8 provided a more consistent and strong knockdown compared to #7.  Our data 
suggest that the EGFR and mTOR pathways converge on eIF4B and when both 
pathways are inhibited, eIF4B is also inhibited, stalling translation initiation and 
regulating the observed synergy.  
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Figure 14: eIF4B phosphorylation is a fragile point in EGFR and mTOR signaling.	  	  
	  
	  
	  
	  
 
 
Immunoblot analysis of TNBC cells after treatment with 1 µM gefitinib (GEF) and/or 
temsirolimus (TEM) for 24 hours.  Lysates were collected and blotted for eIF4 family 
member expression and phosphorylation after electrophoresis on a SDS-PAGE gel. 
eIF4B phosphorylation is completely abrogated with the combination treatment and only 
changes minimally when treated with single agent GEF or TEM in all three cell lines. 
Other family members remain phosphorylated across the treatments. 
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Taken together our data suggest that the regulation of translation initiation may be a 
critical component of EGFR and mTOR inhibitor synergy in TNBC. 
7.2.3 P70S6K and P90RSK are responsible for phosphorylating eIF4B 
downstream of EGFR and mTOR signaling 
Our data suggest that eIF4B is a point of convergence between the EGFR and 
mTOR pathways. P90RSK and P70S6K are two kinases that phosphorylate eIF4B on 
Ser422 (Shahbazian et al., 2006). P90RSK is a downstream effector of EGFR through 
Ras-MAPK activation and P70S6K is downstream of PI3K/mTOR activation (Raught et 
al., 2004). Through P90RSK activation, eIF4B is phosphorylated after growth factor 
signaling from EGFR and a complex signaling network (Yarden and Sliwkowski, 2001). 
To determine if P90RSK and P70S6K are involved in the activation of eIF4B 
downstream of EGFR and mTOR in TNBC, we treated the cell lines with gefitinib and/or 
temsirolimus then measured phosphorylation of P90RSK and P70S6K as surrogates for 
activation of each protein through immunoblotting.  We found that p-P90RSK (S380) 
was inhibited with the combination of gefitinib and temsirolimus while remaining 
activated with single agent treatment with gefitinib and temsirolimus (Figure 16). 
Additionally, P70S6K phosphorylation is abrogated through mTOR inhibition and 
immunoblotting showed inhibition with single agent treatment of temsirolimus and the 
combination (Figure 16). Taken together, our results suggest both P90RSK and 
P70S6K are kinases in the EGFR and mTOR pathways that may be responsible for 
signaling to translation machinery through eIF4B in TNBC.  
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Figure 15: eIF4B knockdown has a similar effect on cell viability as gefitinib and 
mTOR combination.  
	  
When eIF4B is knocked down through siRNA  (#7, 8) there is a significant decrease in 
cell viability similar to that of the combination treatment of GEF+TEM (1 µM) in MDA-
MB-231 cells. Viability was determined through MTT assay after 72 hour drug treatment 
and knock down. Immunoblotting of a concurrent 6-well plate shows #7 and #8 
successfully knocked down eIF4B while the nonsilencing (non-silen) control had no 
effect on protein levels.  
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Figure 16: P70S6K and P90RSK are responsible for phosphorylating eIF4B 
downstream of mTOR and EGFR signaling.  
 
 
 
 
 
TNBC cells were treated with 1 µM gefitinib (GEF), 1 µM temsirolimus (TEM) or the 
combination.  Lysates were collected and  immunoblotted with the indicated antibodies. 
p-P90RSK is decreased with the combination  while remaining active with single agent 
treatment. p-P70S6K is inhibited through temsirolimus treatment alone and is a known 
downstream target of mTOR inhibition. Both kinases are responsible for 
phosphorylating eIF4B and provide a link between EGFR and mTOR signaling which 
must be inhibited to get the observed synergy in BT20, MDA-MB-231, and MDA-MB-
468 cell lines. P90RSK is activated through EGFR signaling and P70S6K through 
mTOR.  
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7.2.4 P90RSK and P70S6K inhibition display similar characteristics to EGFR and 
mTOR synergy  
 P90RSK and P70S6K are kinases that directly phosphorylate eIF4B (Shahbazian 
et al., 2006). Our data suggest that when treated with temsirolimus, P70S6K was 
dephosphorylated but only the combination of GEF+TEM was able to inhibit 
phosphorylation of P90RSK. To more specifically test the effect of the 
dephosphorylation of P70S6K and P90RSK on eIF4B we used two selective inhibitors 
of P90RSK and P70S6K, BI-D1870 and AT7867, respectively (Table 9). As seen with 
GEF+TEM combination treatment, when BI-D1870 and AT7867 (BI+AT) were combined 
in all experimental cell lines, the combination was synergistic (Table 9).  Figure 17 
further shows a decrease in p-eIF4B only when treated with BI+AT. We tested the 
growth effects of BI-D1870 and AT7867 on the TNBC cell lines over an 8 day period as 
described previously. We saw a significant decrease in cell growth with single agent 
treatment (BI orange and AT green line) but the combination of BI+AT (grey line) 
decreased growth to the greatest extent (Figure 18). Together, our data demonstrate 
that dual inhibition of P90RSK and P70S6K displays a similar phenotype as the EGFR 
and mTOR inhibitor combination, further implicating P90RSK and P70S6K in the 
pathway conferring synergy in TNBC cell lines. 
7.2.5 Inhibiting EGFR and mTOR blocks cap-dependent translation 
 Eukaryotic cells use two types of translation, cap-dependent, and cap-
independent also known as internal ribosome entry site (IRES) translation (Merrick, 
2004). Most proteins (95-97%) are translated through the cap-dependent machinery 
and therefore utilize the eIF proteins to mediate translation, but cap-independent 
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translation is possible for transcripts that have a special mRNA sequence that can bind 
the ribosome without the cap (Merrick, 2004; van Gorp et al., 2009; Wendel et al., 
2004). We utilized a dual luciferase assay, which is able to measure both cap-
dependent and cap-independent translation simultaneously after treatment with gefitinib 
and temsirolimus. This allowed us to look at the effects of gefitinib and temsirolimus on 
eIF4B activity through a measurement of its role in translation. Using the reporter 
plasmid (11510:pFR_HCV_xb) we can measure the expression of firefly luciferase as 
regulated by cap-dependent translation and the expression of renilla luciferase 
regulated by cap-independent translation (Petersen et al., 2006). The two types of 
translation were measured using a dual injector plate reader (Figure 19). Data are 
presented as normalized cap-dependent/ cap-independent translation. There was a 
significant decrease (p<0.05) in cap-dependent translation after combination treatment 
of gefitinib and temsirolimus that was not observed with single agent treatment while 
cap-independent translation remained unchanged by the drug treatments. Our results 
suggest the combination treatment only decreases cap-dependent translation most 
likely through the modulation of eIF4B. Treatment has a negligible effect on cap-
independent translation, which does not require eIF4B.  
7.3 Conclusions 
Direct inhibition of P90RSK and P70S6K further implicates eIF4B as an important 
regulatory point downstream of EGFR and mTOR pathways and upon which they 
converge to regulate translational control. Since the vast majority of proteins translated 
within the cell are through a cap-dependent mechanism and therefore require eIF4B, a 
potential mechanism of action for gefitinib and temsirolimus synergy is through inhibiting 
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the translation of many proteins in TNBC cell lines (Merrick, 2004). The importance of 
translation in cancer is beginning to gain notoriety in the field and our data provide 
further evidence suggesting translational control can play a major role in regulating drug 
efficacy. EGFR and mTOR are two well-studied signaling proteins and much is known 
about their pathways. However, our data suggest an important crosstalk between the 
two signaling cascades that converge on eIF4B to regulate translational control and this 
process may be exploited in drug development for TNBC. 	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Table 9: GI50 values and synergy of BI-D1870 and AT7867.  
 	  
 BI-D1870 
(RSK inhib) 
AT7867  
(S6K inhib) 
BI+AT CI value 
BT20 7.41 µM 5.93 µM 2.73 µM 0.66 
MDA-MB-231 9.57 µM 25.5 µM 3.24 µM 0.32 
MDA-MB-468 5.79 µM 8.58 µM 3.54 µM 0.29 
 
The GI50 values for the P90RSK inhibitor BI-D1870 and the P70S6K inhibitor AT7867 
are presented. The CI values were also calculated using CalcuSyn software and the 
combination was found to be synergistic in all three TNBC cell lines. BT20 CI<0.66, 
MDA-MB-231 CI<0.32, MDA-MB-468 CI<0.29.  
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Figure 17: BI-D1870 and AT7867 deceases p-eIF4B. 
 
 
	  	  	  	  
Combination treatment with BI-D1870 and AT7867 decreases p-eIF4B. Single agent 
inhibition of p-P90RSK and p-P70S6K had minimal effects at decreasing the respective 
kinases but when combined abrogate signaling.  	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Figure 18: Growth assays with BI-D1870 and AT7867. 
 
 
	  	  	  
Cell growth assays were done on MDA-MB-468 cells over 8 days in triplicate. Cells 
were treated every other day with 10 µM BI-1870 (BI) and/ or AT7867 (AT) and counted 
on days 1, 4, and 8 with a hemacytometer. ANOVAs were performed on GraphPad 
Prism software with a significant decrease with the combination of BI and AT compared 
to NT and single treatment p*<0.05. There was also a significant decrease between NT 
and AT in all cell lines and also in between NT and BI in BT20 and MDA-MB-231 
p*<0.05. 	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Figure 19: Inhibiting EGFR and mTOR signaling blocks cap-dependent 
translation.  
	   	  	  
 
The plasmid 11510:pFR_HCV_xb was transfected into HEK293T cells to measure cap-
dependent translation through firefly luciferase and cap-independent translation through 
renilla luciferase. Luciferase was measured using a dual-luciferase reporter assay 
system from whole cell lysates. Values within each experiment were normalized to 1.0 
as NT (no treatment). Relative light units from the firefly luciferase was plotted over 
relative light units from the renilla luciferase. Each experiment was performed in 
triplicate at least two times. There is a significant decrease (p<0.05) in translation with 
GEF+TEM (blue bar) treatment. Treatments were for 24 hours at 1 µM. The decrease in 
cap-dependent translation is further evidence implicating eIF4B dephosphorylation 
through EGFR and mTOR inhibition is important in translation regulation. eIF4B 
provides a point of convergence for the EGFR and mTOR pathways and their role in 
regulating translation initiation.  	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CHAPTER 8: STAT3 signaling in EGFR and mTOR synergy in TNBC 
8.1 Introduction 
STATs are known to play a role in many types of cancer including lung, breast, 
and prostate (Quesnelle et al., 2007). These transcription factors can be activated by 
cell surfaces receptors such as EGFR, and by mediary proteins including JAK and 
mTOR before they translocate to the nucleus and control the transcription of certain 
genes (Buettner et al., 2002). STAT3 is a known oncogene that has been studied in a 
variety of cancers including lung, gastric, and breast (Table 5). The association of 
STAT3 with EGFR and mTOR has been previously explored in gastric cancer and was 
found to be a negative prognostic marker (Inokuchi M  et al., 2011). Elevated 
expression of all three proteins within the gastric tumor correlated with a higher grade 
and stage.  Important to this work, STAT3 can be phosphorylated on two sites by EGFR 
(Y705) and mTOR (S727) respectively. Both sites must be phosphorylated for full and 
robust activation of STAT3. Signaling input from both the membrane bound EGFR and 
cytoplasmic mTOR protein enable STAT3 to be controlled by many signals leading to 
the transcription of genes often associated with a proliferative and tumorigenic 
phenotype.  
8.2 Results 
8.2.1 STAT3 phosphorylation is lost in response to gefitinib and temsirolimus 
Early studies found STAT3 as a potential target of EGFR/mTOR dual inhibition. 
Specifically, we found a decrease in phosphorylation of STAT3 in all three TNBC cell 
lines tested when treated with GEF+TEM while single agent treatment had no effect 
(Figure 20). The phosphorylation of both Y705 and S727 was only decreased with the 
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combination treatment. The continued phosphorylation of the individual sites with single 
agent treatment further demonstrates TNBC cell line drug resistance to temsirolimus 
and gefitinib as the EGFR is still able to signal to Y705 and mTOR to S727, 
respectively. Only the combination causes a decrease in p-STAT3. These data suggest 
that, similar to the phosphorylation of eIF4B, STAT3 may be a mediator of gefitinib and 
temsirolimus synergy in TNBC. 
8.2.2 A STAT3 inhibitor decreases cell viability and abrogates EGFR and mTOR 
fragile point signaling 
We sought to further investigate the role of p-STAT3 in conferring the synergy we 
observe with EGFR and mTOR inhibitors. To determine if an inhibitor of STAT3 mimics 
gefitinib and temsirolimus dual treatment, we utilized the STAT3 inhibitor (STATTIC). 
STATTIC is a small molecule inhibitor that inhibits the dimerization domain of STAT3 
and its phosphorylation at Y705 abrogating the transcription factor’s ability to signal. As 
seen in Figure 21, STATTIC inhibits STAT3 phosphorylation to a greater extent than the 
decrease seen in GEF+TEM as expected since it is a direct inhibitor. We then used 
STATTIC treated cells and measured phosphorylation of other proteins in our predicted 
EGFR and mTOR synergy pathway. A constitutively active Stat3c plasmid (described 
below) was also used to overexpress active STAT3 and measure the effect on 
phosphorylation of the proteins. We observed that STAT3 overexpression increased the 
phosphorylation. Our data propose that STATTIC is able to abrogate p-P70S6K, p-
P90RSK, and p-eIF4B while Stat3c increases phosphorylation in p-P90RSK and p-
eIF4B (Figure 21). The data suggest that STAT3 may also have a role in regulating 
eIF4B and P90RSK and, when STAT3 is dephosphorylated, eIF4B and P90RSK are 
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inactivated. While these results are preliminary and much more work would need to be 
done to validate the role of STAT3 as an upstream signal or transcriptional regulator of 
P90RSK and P70S6K, our data give exciting evidence for a more intricate crosstalk 
mechanism within the cell.  
8.2.3 Constitutively active STAT3 blocks gefitinib and temsirolimus synergy in 
TNBC 
Our results suggest STAT3 may play a role in regulating EGFR and mTOR 
inhibitor synergy in TNBC cell lines. To further study the importance of STAT3 we 
utilized a constitutively active STAT3 plasmid (Stat3c) transfected into TNBC cells and 
then treated with gefitinib and temsirolimus to assess synergy.  If STAT3 plays a vital 
role in regulating EGFR and mTOR inhibitor synergy through its decreased 
phosphorylation, a constitutively active STAT3 would negate the synergy. Gefitinib and 
temsirolimus would be unable to modulate STAT3 activity and turn off the downstream 
signaling pathways.  Therefore, we performed MTT viability assays to determine if the 
GEF+TEM combination had the same synergistic effect when STAT3 remained 
phosphorylated through transfection of Stat3c.  
Transfection efficiency as observed through the GFP tag on Stat3c is only about 
30% in MDA-MB-231 and MDA-MB-468 cells and lower in BT20 (Figure 22 white cells 
in Stat3c row compared to cells in Brightfield row, estimated transfection efficiency 
based on visualized GFP positive cells). Immunoblotting for p-STAT3 performed 
alongside the MTT viability study, shows after 72 hours, there is a marked increase in p-
STAT3 (Y705) suggesting that the cells transfected with Stat3c do contain higher levels 
of constitutively active STAT3. To determine if gefitinib and temsirolimus treatment   
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Figure 20: Gefitinib and temsirolimus combination decreases p-STAT3.  
 	  	  
	  	  
TNBC cells were treated with 1 µM gefitinib (GEF), 1 µM temsirolimus (TEM) or the 
combination.  Lysates were collected and immunoblotted with the indicated antibodies. 
p-STAT3 (Y705) and (S727) are decreased with the combination  while remaining active 
with single agent treatment. Both sites must be phosphorylated for full activation of 
STAT3.  
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Figure 21: STAT3 inhibition through STATTIC decreases EGFR and mTOR 
regulated proteins. 
  	  
	  	  
STAT3 inhibition through STATTIC treatment decreases EGFR and mTOR related 
proteins including p-eIF4B, p-P90RSK and p-P70S6K in a similar manner to EGFR and 
mTOR dual inhibition through GEF+TEM. Stat3c transfected cells have increased 
phosphorylation of proteins.  
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Figure 22: Constitutively active STAT3 by Stat3c plasmid negates gefitinib and 
temsirolimus synergy in TNBC cell lines. 
 
  
 
	  
Stat3c constitutively active plasmid was transfected into TNBC cells over 72 hours. 
Immunoblotting was done to measure protein phosphorylation while fluorescent images 
were also taken measuring transfection efficiency through the GFP tag on Stat3c. MDA-
MB-231 and MDA-MB-468 cells had the best transfection as measured though GFP and 
immunoblotting. MTT cell viability assays were also done to determine gefitinib and 
temsirolimus combination effect on the cells lines with Stat3c. CI values were calculated 
using CalcuSyn software and the CI>1.0. BT20 CI<2.23, MDA-MB-231<1.07, MDA-MB-
468 <1.48. GFP positive green cells were changed to grey scale for better visualization 
when printed to appear white on a black background instead of green.  
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remained synergistic in cells transfected with Stat3c, synergy studies were performed 
as described above in section 3.4 Using CalcuSyn to calculate the CI values in the 
presence of Stat3c, we found that all three cell lines no longer exhibited synergy in 
response to gefitinib and temsirolimus (CI=2.23 for BT20, CI=1.07 for MDA-MB-231, 
and CI=1.48 for MDA-MB-468). These results support a role for STAT3 in regulating the 
synergy observed when TNBC cells are treated with EGFR and mTOR inhibitors.  
8.2.4 EGFR and mTOR inhibitors block STAT3 DNA binding 
After STAT3 is phosphorylated it can homo- or heterodimerize, then translocate 
to the nucleus to bind STAT3 DNA-binding elements and control gene expression 
(Furqan et al., 2013). We have previously shown that GEF+TEM combination is able to 
decrease STAT3 phosphorylation on both Y705 and S727 (Figure 20). In order to 
measure STAT3 activity we utilized an ELISA (Figure 23). The ELISA is able to 
qualitatively measure sample binding to a STAT3 response element oligo allowing us to 
determine the effect of drug treatment on STAT3 activity. We found that MDA-MB-231 
cells when treated with single agent gefitinib and temsirolimus (red and green bars) had 
minimal effect on DNA binding ability. However, the combination (GEF+TEM, blue bar) 
showed a significant decrease in STAT3 activity (p*<0.05). STATTIC treatment also had 
a significant decrease in DNA binding. Taken together, our results suggest that EGFR 
and mTOR dual inhibition decreases STAT3 phosphorylation on both Y705 and S727 to 
modulate DNA binding. This decrease in STAT3 DNA binding is another mechanism of 
action that may be responsible for the synergistic effects of gefitinib and temsirolimus in 
TNBC cell lines.  
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8.3 Conclusions 
Immunoblot studies showed a decrease in STAT3 phosphorylation on both Y705 
and S727 in response to GEF+TEM combination, while single agent treatment had no 
effect on phosphorylation. Further studies demonstrated that inhibition of STAT3 
through a small molecule inhibitor, STATTIC, decreased cell viability and also inhibited 
the phosphorylation of interested proteins in the EGFR/mTOR pathway that are 
important in regulating synergy; P90RSK, P70S6K, and eIF4B. Through constitutive 
activation of STAT3 via plasmid transfection, we were able to negate the previously 
observed synergy of GEF+TEM in all three TNBC cell lines suggesting that the 
decreased phosphorylation of STAT3 is an important mediator of the EGFR and mTOR 
inhibitor synergy. DNA binding ability of STAT3 was also significantly decreased when 
treated with the drug combination. Our results provide evidence that STAT3 is an 
important mediator of EGFR/mTOR inhibitor synergy in TNBC.	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Figure 23: Gefitinib and temsirolimus in combination significantly decrease 
STAT3 DNA binding. 
 
 
STAT3 DNA binding was measured through an ELISA. There is a significant decrease 
in DNA binding when treated with the GEF+TEM combination and STATTIC that is 
absent in single agent treatment. p*<0.05 **<0.01 
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CHAPTER 9: Conclusions 
While survival rates for breast cancer patients are rising, those with TNBC 
continue to have no suitable and successful drug therapy other than standard cytotoxic 
chemotherapy. These patients do not respond to common hormone and HER2 driven 
therapies since they do not express the cellular targets. TNBC patients have limited 
non-surgical treatment options. Adjuvant cytotoxic chemotherapy is often given but high 
resistance rates are common (Chacon and Costanzo, 2010; Santana-Davila R, 2010). 
Research has been done in TNBC to find an effective targeted therapy that improves 
the response rates while avoiding resistance and treatment limiting side effects. This 
work focused on the overexpression of EGFR as TNBC often expresses high levels of 
the receptor. Inhibitors targeting the EGFR are approved for different types of cancers 
and, therefore, the receptor has potential to be exploited as a target in TNBC (Hawk, 
2010; Santana-Davila R, 2010). Our research found that the mTOR pathway remained 
activated in EGFR inhibitor resistant TNBC cell lines. Further evidence suggests that 
mTOR and EGFR inhibitor combination has a synergistic effect at decreasing TNBC cell 
viability and significantly decreases growth and colony formation. Our data confirm the 
findings of others studying colon, prostate, and breast cancers that suggest the use of 
mTOR inhibitors in combination with EGFR inhibitors to be of potential benefit (Bianco 
et al., 2008; Liu et al., 2011). Everolimus was shown to sensitize GEO colon, PC3 
prostate, and MDA-MB-468 TNBC cells to gefitinib and cetuximab and decrease their 
growth in a dose-dependent manner. Using mouse xenografts the study showed a 
decrease in colon cancer tumor burden by 90% when the drugs were used in 
combination (Bianco et al., 2008). While EGFR inhibitors as monotherapy have not 
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been effective due to intrinsic resistance, our results and those of others suggest that 
combinations of EGFR and mTOR inhibitors are synergistic and their combined 
potential as a targeted therapy in TNBC needs to be further studied (Liu et al., 2011; 
O'Regan and Hawk, 2011). 
Similar to published studies, our work found that dual treatment with gefitinib and 
temsirolimus had a synergistic effect on decreasing TNBC cell viability, growth, and 
clonogenic survival. While the combination of EGFR and mTOR inhibitors has been 
previously observed in TNBC, the mechanism of synergy is not understood. Our studies 
found an EGFR and mTOR crosstalk involving eIF4B and STAT3 that provides 
evidence for regulating the observed synergy.  
Inhibiting both EGFR and mTOR signaling was required to abrogate eIF4B 
phosphorylation and subsequent cap-dependent translation in TNBC cell lines.  Cancer 
cells have an increased metabolic and proliferative rate requiring a high demand for 
available protein. Aberrant translation has been implemented in cancer progression for 
a number of years as patients with ribosomal disorders have an increased cancer risk 
(Loreni et al., 2013; Montanaro et al., 2012). eIF4E is often considered an oncogene as 
it was shown to induce transformation in cells (Lazaris-Karatzas et al., 1990). eIF4E is a 
member of initiation factors that have altered expression in different types of cancer 
(Silvera et al., 2010). Current research has also explored the potential benefit of 
targeting the eIF4F complex in BRAF inhibitor resistant melanoma, colon, and thyroid 
cancer cell lines. The authors, published in the most current issue of Nature, reported 
that patient tumors resistant to inhibitors had increased activation of eIF4F resulting in 
higher cap-dependent translation (Boussemart et al., 2014). In the same issue, another 
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group discovered the oncogene ability of eIF4A in T-ALL and an inhibitor of eIF4A was 
able to decrease ALL cell growth (Wolfe et al., 2014). It was previously discovered that 
the MAPK and mTOR/PI3K pathways converge on eIF4B but to our knowledge this is 
the first evidence of EGFR and mTOR inhibitor synergy being regulated by eIF4B in 
TNBC (Shahbazian et al., 2006). Taken together, these results have identified a new 
fragile point, eIF4B phosphorylation, and cap-dependent translation as a mediator of 
EGFR and mTOR crosstalk in TNBC. 
Our results suggest that the common EGFR and mTOR signaling proteins, 
MAPK and AKT, are not responsible for regulating the synergy. Inhibiting EGFR and 
mTOR through gefitinib and temsirolimus had no effect on MAPK and AKT 
phosphorylation. This result corresponds with other studies in colon and lung cancer 
that found AKT and MAPK maintain activity after EGFR and mTOR inhibitor treatment 
(Bianco et al., 2008; La Monica et al., 2009). While MAPK and AKT are often 
considered the main signaling proteins for the EGFR and mTOR pathways, 
respectively, our data suggest a more prominent role for P70S6K and P90RSK in TNBC 
cell lines resistant to EGFR inhibitors. P90RSK is downstream of MAPK and known to 
be up regulated in breast and prostate cancer. It can activate P70S6K through direct 
phosphorylation or through mTOR activation (Clark et al., 2005; Hennessy et al., 2005; 
Romeo and Roux, 2011). Both P90RSK and P70S6K are involved in protein translation 
through their ability to directly phosphorylate eIF4B. P70S6K is also known to 
phosphorylate another key translation factor, 4E-BP1. When 4E-BP1 is phosphorylated 
it releases eIF4E, the rate-limiting step in translation initiation, allowing it to form the 
eIF4F complex initiating translation. Our data suggest that P70S6K regulation through 
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EGFR and mTOR inhibition acts independently of 4E-BP1 as immunoblotting indicates 
no change in 4E-BP1 phosphorylation after treatment (data not shown). Instead the 
gefitinib and temsirolimus combination inhibits eIF4B phosphorylation through P70S6K 
and P90RSK inhibition and decreases cap-dependent translation leading to the synergy 
we observe in TNBC cell lines. 
STAT3 is a transcription factor that is implicated in the oncogenesis of many 
types of cancer, including breast. It can be activated through a variety of signaling 
proteins including EGFR and mTOR, which bind to individual phosphorylation sites 
(Y705 and S727, respectively), both of which are required for full activation of STAT3. 
Our data suggest STAT3 phosphorylation selectively decreases with GEF+TEM 
combination while remaining unchanged with single agent treatment. Further evidence 
using STATTIC, a STAT3 inhibitor, and Stat3c constitutively active plasmid found that 
specific STAT3 activation is able to negate the synergistic effect we observe with 
GEF+TEM as measured through cell viability MTT assays. Our data suggest that, 
similar to eIF4B regulation, STAT3 is regulated downstream of EGFR and mTOR 
signaling and may be responsible for regulating TNBC cell synergy.   
Our studies identified EGFR and mTOR inhibitors as a potentially effective 
treatment for TNBC and the drug combination needs to be further explored.  In addition, 
these studies suggest P90RSK and P70S6K must be abrogated to mediate the 
synergistic effects of gefitinib and temsirolimus combination. The effect translation has 
on cancer cells in regard to the mTOR and EGFR pathways is largely unexplored in 
TNBC and further implicates eIF4B as a protein of interest in understanding the gefitinib 
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and temsirolimus synergy. We further present evidence suggesting that STAT3 may 
also play a role in regulating synergy through DNA binding control.  
TNBC has limited therapeutic options and this project sought to find a drug 
combination to circumvent EGFR resistance using a phospho-proteomic approach. 
While EGFR and mTOR inhibitors are approved in the clinic for various types of cancer. 
Confirming the results of others, we suggest a potential use for EGFR/ mTOR inhibitor  
combination in TNBC that needs to be further explored. The mechanism of action for 
their observed synergy was previously unknown but we suggest it is through 
translational control by eIF4B, and transcriptional regulation by STAT3. TNBC is a 
highly malignant disease and through the data presented in this dissertation, another 
therapeutic option may become available for patients in the future.  	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APPENDIX 
Supplemental Figure 1: Proposed pathway diagram. 
 
 
 
Proposed pathway involving EGFR and mTOR proteins that are involved in regulating 
synergy to gefitinib and temsirolimus combination in TNBC cell lines. Only when used in 
combination do the drugs inhibit eIF4B to reduce translation and STAT3 to control 
transcription. Dashed lines between mTOR, P90RSK, and P70S6K indicate the ability of 
these proteins to activate each other. Additionally, there may be an extra level of control 
involving STAT3 regulation of eIF4B and P90RSK (dashed lines) that also contribute to 
the observed synergy and decreases in growth and survival.  
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Supplemental Table 1: Proteins identified by phospho-mass spectrometry as not    
significantly changed after gefitinib treatment. 
 
Gene description Accession Number 
182 kDa tankyrase-1-binding protein TB182_HUMAN 
3-hydroxyacyl-CoA dehydratase 3  HACD3_HUMAN 
3-phosphoinositide-dependent protein kinase 1  PDPK1_HUMAN (+1) 
40S ribosomal protein S3 OS=Homo sapiens  RS3_HUMAN 
60S acidic ribosomal protein P0  RLA0_HUMAN (+1) 
60S acidic ribosomal protein P1  RLA1_HUMAN (+1) 
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 
2  F262_HUMAN 
Acetyl-coenzyme A synthetase, cytoplasmic  ACSA_HUMAN 
Adenylyl cyclase-associated protein 1  CAP1_HUMAN 
Alpha- and gamma-adaptin-binding protein p34  AAGAB_HUMAN 
Alpha-taxilin OS=Homo sapiens  TXLNA_HUMAN 
AMP deaminase 2 OS=Homo sapiens  AMPD2_HUMAN 
Antigen KI-67 OS=Homo sapiens  KI67_HUMAN 
AP2-associated protein kinase 1  AAK1_HUMAN 
AP-3 complex subunit delta-1 AP3D1_HUMAN 
Arfaptin-1 OS=Homo sapiens  ARFP1_HUMAN 
Astrocytic phosphoprotein PEA-15  PEA15_HUMAN 
Ataxin-2-like protein  ATX2L_HUMAN 
ATP-binding cassette sub-family F member 1  ABCF1_HUMAN 
AT-rich interactive domain-containing protein 1A  ARI1A_HUMAN 
BAG family molecular chaperone regulator 3  BAG3_HUMAN 
Bcl-2-associated transcription factor 1 BCLF1_HUMAN 
Beta-2-syntrophin SNTB2_HUMAN 
Bifunctional aminoacyl-tRNA synthetase  SYEP_HUMAN 
Brefeldin A-inhibited guanine nucleotide-exchange 
protein 2  BIG2_HUMAN 
Bystin  BYST_HUMAN 
CAD protein  PYR1_HUMAN 
Calnexin  CALX_HUMAN 
cAMP-dependent protein kinase type I-alpha 
regulatory subunit  KAP0_HUMAN 
cAMP-dependent protein kinase type II-alpha 
regulatory subunit  KAP2_HUMAN 
Catenin alpha-1  CTNA1_HUMAN 
Catenin delta-1  CTND1_HUMAN 
Cation-independent mannose-6-phosphate receptor  MPRI_HUMAN 
102	  	  
	  	  
CCAAT/enhancer-binding protein beta  CEBPB_HUMAN 
Cleavage and polyadenylation specificity factor 
subunit 2  CPSF2_HUMAN 
Cleavage stimulation factor subunit 3  CSTF3_HUMAN 
Coatomer subunit beta'  COPB2_HUMAN 
Cofilin-1  COF1_HUMAN 
Coiled-coil domain-containing protein 6  CCDC6_HUMAN 
Coiled-coil domain-containing protein 86  CCD86_HUMAN 
CTTNBP2 N-terminal-like protein  CT2NL_HUMAN 
Cyclin-dependent kinase 1  CDK1_HUMAN 
Cyclin-dependent kinase 12  CDK12_HUMAN 
Death-associated protein 1  DAP1_HUMAN 
Death-inducer obliterator 1  DIDO1_HUMAN 
Density-regulated protein DENR_HUMAN 
Destrin DEST_HUMAN 
DNA repair protein complementing XP-C cells  XPC_HUMAN 
DNA repair protein XRCC1  XRCC1_HUMAN 
DNA replication licensing factor MCM2 MCM2_HUMAN 
DNA topoisomerase 2-beta  TOP2B_HUMAN 
DOCK3_HUMAN-R DOCK3_HUMAN-R 
Double-strand break repair protein MRE11A MRE11_HUMAN 
Drebrin-like protein  DBNL_HUMAN 
Dual specificity testis-specific protein kinase 1  TESK1_HUMAN 
Dynein heavy chain 14, axonemal DYH14_HUMAN 
E3 SUMO-protein ligase RanBP2  RBP2_HUMAN 
E3 ubiquitin-protein ligase BRE1A  BRE1A_HUMAN 
E3 ubiquitin-protein ligase CHIP  CHIP_HUMAN 
E3 ubiquitin-protein ligase HUWE1 HUWE1_HUMAN 
E3 ubiquitin-protein ligase TRIM33  TRI33_HUMAN 
E3 ubiquitin-protein ligase ZFP91  ZFP91_HUMAN 
Echinoderm microtubule-associated protein-like 4  EMAL4_HUMAN 
EFCB6_HUMAN-R EFCB6_HUMAN-R 
Elongation factor 1-beta EF1B_HUMAN 
Elongation factor 1-delta  EF1D_HUMAN 
Enhancer of mRNA-decapping protein 4  EDC4_HUMAN 
Epidermal growth factor receptor kinase substrate 8-
like protein 2  ES8L2_HUMAN 
Epidermal growth factor receptor  EGFR_HUMAN 
Epiplakin EPIPL_HUMAN 
Eukaryotic translation initiation factor 2A  EIF2A_HUMAN 
Eukaryotic translation initiation factor 3 subunit B  EIF3B_HUMAN 
Eukaryotic translation initiation factor 3 subunit C  EIF3C_HUMAN 
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Eukaryotic translation initiation factor 3 subunit D  EIF3D_HUMAN 
Eukaryotic translation initiation factor 3 subunit G  EIF3G_HUMAN 
Eukaryotic translation initiation factor 3 subunit J  EIF3J_HUMAN 
Eukaryotic translation initiation factor 4 gamma 1 IF4G1_HUMAN 
Eukaryotic translation initiation factor 4E-binding 
protein 1 4EBP1_HUMAN 
Eukaryotic translation initiation factor 5 IF5_HUMAN 
Eukaryotic translation initiation factor 5B  IF2P_HUMAN 
FACT complex subunit SSRP1  SSRP1_HUMAN 
Fatty acid synthase FAS_HUMAN 
Ferritin heavy chain  FRIH_HUMAN 
FH1/FH2 domain-containing protein 1  FHOD1_HUMAN 
FIL1L_HUMAN-R FIL1L_HUMAN-R 
Filensin BFSP1_HUMAN 
FK506-binding protein 15 FKB15_HUMAN 
General transcription factor II-I  GTF2I_HUMAN 
Glucocorticoid receptor DNA-binding factor 1  GRLF1_HUMAN 
Glucosamine--fructose-6-phosphate aminotransferase 
[isomerizing] 1  GFPT1_HUMAN 
Glycogen [starch] synthase, muscle  GYS1_HUMAN 
Glycogen synthase kinase-3 alpha  GSK3A_HUMAN (+1) 
Golgi reassembly-stacking protein 2  GORS2_HUMAN 
Golgi-specific brefeldin A-resistance guanine 
nucleotide exchange factor 1  GBF1_HUMAN 
H/ACA ribonucleoprotein complex subunit 4  DKC1_HUMAN 
Heat shock protein beta-1  HSPB1_HUMAN 
Heat shock protein HSP 90-alpha HS90A_HUMAN 
Heat shock protein HSP 90-beta  HS90B_HUMAN (+1) 
Hepatoma-derived growth factor HDGF_HUMAN 
Heterogeneous nuclear ribonucleoprotein H  HNRH1_HUMAN (+1) 
Heterogeneous nuclear ribonucleoprotein K  HNRPK_HUMAN 
Heterogeneous nuclear ribonucleoprotein U  HNRPU_HUMAN 
Heterogeneous nuclear ribonucleoprotein U-like 
protein 1  HNRL1_HUMAN 
Heterogeneous nuclear ribonucleoprotein U-like 
protein 2  HNRL2_HUMAN 
Heterogeneous nuclear ribonucleoproteins A2/B1  ROA2_HUMAN 
High mobility group protein HMG-I/HMG-Y  HMGA1_HUMAN 
Histone deacetylase 2  HDAC2_HUMAN 
Histone demethylase UTY  UTY_HUMAN 
Histone H1.2  H12_HUMAN 
Histone H1.5  H15_HUMAN 
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HIV Tat-specific factor 1  HTSF1_HUMAN 
Hsc70-interacting protein  F10A1_HUMAN 
IFRD2_HUMAN-R IFRD2_HUMAN-R 
Interferon regulatory factor 2-binding protein 2  I2BP2_HUMAN 
Interferon regulatory factor 2-binding protein-like  I2BPL_HUMAN 
KDM6A_HUMAN-R KDM6A_HUMAN-R 
Kelch domain-containing protein 4  KLDC4_HUMAN 
Keratin, type I cytoskeletal 18  K1C18_HUMAN 
Keratin, type I cytoskeletal 19  K1C19_HUMAN 
Keratin, type II cytoskeletal 5 K2C5_HUMAN 
Keratin, type II cytoskeletal 7 K2C7_HUMAN 
Keratin, type II cytoskeletal 8  K2C8_HUMAN 
Kinectin  KTN1_HUMAN 
Lamina-associated polypeptide 2, isoform alpha  LAP2A_HUMAN (+1) 
La-related protein 1  LARP1_HUMAN 
La-related protein 4  LARP4_HUMAN 
Large proline-rich protein BAG6  BAG6_HUMAN 
LIM and SH3 domain protein 1 LASP1_HUMAN 
LIM domain and actin-binding protein 1  LIMA1_HUMAN 
Lupus La protein LA_HUMAN 
Lysine-specific histone demethylase 1A  KDM1A_HUMAN 
Mediator of DNA damage checkpoint protein 1 MDC1_HUMAN 
Membrane-associated progesterone receptor 
component 1  PGRC1_HUMAN 
Membrane-associated progesterone receptor 
component 2  PGRC2_HUMAN 
Methylosome subunit pICln  ICLN_HUMAN 
Microcephalin MCPH1_HUMAN 
Microfibrillar-associated protein 1  MFAP1_HUMAN 
Misshapen-like kinase 1  MINK1_HUMAN 
Mitochondrial import receptor subunit TOM22 homolog  TOM22_HUMAN 
Mitogen-activated protein kinase 1  MK01_HUMAN 
Mitotic checkpoint protein BUB3  BUB3_HUMAN 
Monocarboxylate transporter 1  MOT1_HUMAN 
Myb-binding protein 1A MBB1A_HUMAN 
Myc box-dependent-interacting protein 1  BIN1_HUMAN 
Myelin expression factor 2 MYEF2_HUMAN 
Myosin-9  MYH9_HUMAN 
Nardilysin  NRDC_HUMAN 
Negative elongation factor B  NELFB_HUMAN 
Neuroblast differentiation-associated protein AHNAK  AHNK_HUMAN 
Niban-like protein 1 NIBL1_HUMAN 
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Nuclear autoantigen Sp-100  SP100_HUMAN 
Nuclear cap-binding protein subunit 1  NCBP1_HUMAN 
Nuclear pore complex protein Nup98-Nup96  NUP98_HUMAN 
Nuclear ubiquitous casein and cyclin-dependent 
kinases substrate  NUCKS_HUMAN 
Nuclear-interacting partner of ALK  NIPA_HUMAN 
Nuclease-sensitive element-binding protein 1  YBOX1_HUMAN 
Nucleolar and coiled-body phosphoprotein 1  NOLC1_HUMAN 
Nucleolar complex protein 2 homolog  NOC2L_HUMAN 
Nucleolar protein 58  NOP58_HUMAN 
Nucleolar RNA helicase 2  DDX21_HUMAN 
Nucleolin NUCL_HUMAN 
Nucleophosmin  NPM_HUMAN 
Nucleosome assembly protein 1-like 4  NP1L4_HUMAN 
Osteoclast-stimulating factor 1  OSTF1_HUMAN 
Oxysterol-binding protein 1  OSBP1_HUMAN 
Oxysterol-binding protein-related protein 11  OSB11_HUMAN 
Paralemmin-3 PALM3_HUMAN 
Partitioning defective 3 homolog  PARD3_HUMAN 
Paxillin  PAXI_HUMAN 
Periodic tryptophan protein 1 homolog  PWP1_HUMAN 
PERQ amino acid-rich with GYF domain-containing 
protein 2  PERQ2_HUMAN 
PHD and RING finger domain-containing protein 1  PHRF1_HUMAN 
Phosphatidylinositol 4-kinase type 2-alpha  P4K2A_HUMAN 
Pinin  PININ_HUMAN 
Plakophilin-3  PKP3_HUMAN 
Pleckstrin homology-like domain family B member 2  PHLB2_HUMAN 
Plectin  PLEC_HUMAN 
Prelamin-A/C LMNA_HUMAN 
Probable E3 ubiquitin-protein ligase TRIP12  TRIPC_HUMAN 
Proline-, glutamic acid- and leucine-rich protein 1 PELP1_HUMAN 
Proline-rich AKT1 substrate 1 AKTS1_HUMAN 
Proline-rich protein 15  PRR15_HUMAN 
Protein arginine N-methyltransferase 3  ANM3_HUMAN 
Protein capicua homolog  CIC_HUMAN 
Protein FAM83H  FA83H_HUMAN 
Protein kinase C and casein kinase substrate in 
neurons protein 2  PACN2_HUMAN 
Protein KRI1 homolog  KRI1_HUMAN 
Protein PRRC2B  PRC2B_HUMAN 
Protein PRRC2C  PRC2C_HUMAN 
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Protein scribble homolog  SCRIB_HUMAN 
Protein strawberry notch homolog 1 SBNO1_HUMAN 
Protein transport protein Sec61 subunit beta  SC61B_HUMAN 
Putative pre-mRNA-splicing factor ATP-dependent 
RNA helicase DHX16  DHX16_HUMAN 
Putative protein phosphatase inhibitor 2-like protein 1  IPP2L_HUMAN 
Putative protein phosphatase inhibitor 2-like protein 3  IPP2M_HUMAN (+1) 
Rab11 family-interacting protein 1  RFIP1_HUMAN 
Ral GTPase-activating protein subunit alpha-1  RGPA1_HUMAN 
Ras GTPase-activating protein-binding protein 1  G3BP1_HUMAN 
Ras-related protein R-Ras2  RRAS2_HUMAN 
Regulation of nuclear pre-mRNA domain-containing 
protein 1B  RPR1B_HUMAN 
Regulator of microtubule dynamics protein 3  RMD3_HUMAN 
Reticulon-3  RTN3_HUMAN 
Reticulon-4 RTN4_HUMAN 
Retinoic acid-induced protein 3  RAI3_HUMAN 
Rho GTPase-activating protein 10  RHG10_HUMAN 
Rho GTPase-activating protein 12  RHG12_HUMAN 
Rho GTPase-activating protein 17  RHG17_HUMAN 
Rho guanine nucleotide exchange factor 5  ARHG5_HUMAN 
Ribosomal L1 domain-containing protein 1 RL1D1_HUMAN 
RING finger protein 113A  R113A_HUMAN 
RNA-binding protein 39  RBM39_HUMAN 
RNA-binding protein NOB1 NOB1_HUMAN 
RNA-binding protein Raly  RALY_HUMAN 
rRNA/tRNA 2'-O-methyltransferase fibrillarin-like 
protein 1  FBLL1_HUMAN 
Septin-2  SEPT2_HUMAN 
Septin-9  SEPT9_HUMAN 
Serine/arginine repetitive matrix protein 1  SRRM1_HUMAN 
Serine/arginine repetitive matrix protein 2 SRRM2_HUMAN 
Serine/threonine-protein kinase B-raf  BRAF_HUMAN 
Serine/threonine-protein kinase PAK 4  PAK4_HUMAN 
Serine/threonine-protein kinase PRP4 homolog PRP4B_HUMAN 
Serine/threonine-protein kinase SRPK1 SRPK1_HUMAN 
Serine/threonine-protein kinase TAO3  TAOK3_HUMAN 
Signal recognition particle receptor subunit alpha  SRPR_HUMAN 
Sister chromatid cohesion protein PDS5 homolog B  PDS5B_HUMAN 
Small acidic protein  SMAP_HUMAN 
Sodium/hydrogen exchanger 1  SL9A1_HUMAN 
Spectrin beta chain, brain 1  SPTB2_HUMAN 
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Splicing factor 1  SF01_HUMAN 
Splicing factor 3B subunit 2  SF3B2_HUMAN 
Splicing factor, arginine/serine-rich 19  SFR19_HUMAN 
Src substrate cortactin  SRC8_HUMAN 
Stathmin  STMN1_HUMAN 
Striatin  STRN_HUMAN 
Structural maintenance of chromosomes protein 4  SMC4_HUMAN 
Sulfotransferase family cytosolic 2B member 1  ST2B1_HUMAN 
Supervillin  SVIL_HUMAN 
Survival motor neuron protein  SMN_HUMAN 
SWI/SNF-related matrix-associated actin-dependent 
regulator of chromatin subfamily A member 5  SMCA5_HUMAN 
Synapse-associated protein 1  SYAP1_HUMAN 
Synembryn-A  RIC8A_HUMAN 
Target of Myb protein 1  TOM1_HUMAN 
TBC1 domain family member 9B  TBC9B_HUMAN 
Telomeric repeat-binding factor 2-interacting protein 1  TE2IP_HUMAN 
Tensin-3  TENS3_HUMAN 
Thioredoxin-related transmembrane protein 1  TMX1_HUMAN 
Thyroid hormone receptor-associated protein 3  TR150_HUMAN 
Tight junction protein ZO-1  ZO1_HUMAN 
Tight junction protein ZO-2  ZO2_HUMAN 
Tight junction protein ZO-3  ZO3_HUMAN 
Tight junction-associated protein 1  TJAP1_HUMAN 
Torsin-1A-interacting protein 1  TOIP1_HUMAN 
TRAF-type zinc finger domain-containing protein 1  TRAD1_HUMAN 
Transcription intermediary factor 1-beta  TIF1B_HUMAN 
Transcriptional activator protein Pur-beta  PURB_HUMAN 
Transmembrane and coiled-coil domains protein 1  TMCC1_HUMAN 
Transmembrane protein 40  TMM40_HUMAN 
Treacle protein  TCOF_HUMAN 
Triosephosphate isomerase  TPIS_HUMAN 
Tripartite motif-containing protein 16  TRI16_HUMAN 
tRNA (cytosine-5-)-methyltransferase NSUN2 NSUN2_HUMAN 
Tumor protein D54  TPD54_HUMAN 
Tumor suppressor p53-binding protein 1 TP53B_HUMAN 
U3 small nucleolar RNA-associated protein 14 
homolog A  UT14A_HUMAN 
U3 small nucleolar RNA-associated protein 18 
homolog  UTP18_HUMAN 
Ubiquitin carboxyl-terminal hydrolase 10  UBP10_HUMAN 
Ubiquitin-associated protein 2-like  UBP2L_HUMAN 
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Uncharacterized protein C19orf21  CS021_HUMAN 
UPF0414 transmembrane protein C20orf30  CT030_HUMAN 
UV excision repair protein RAD23 homolog B  RD23B_HUMAN 
Vinexin  VINEX_HUMAN 
WD repeat-containing protein 44  WDR44_HUMAN 
WW domain-containing adapter protein with coiled-coil  WAC_HUMAN 
Yorkie homolog  YAP1_HUMAN 
Zinc finger and BTB domain-containing protein 7A  ZBT7A_HUMAN 
Zinc finger CCCH-type antiviral protein 1  ZCCHV_HUMAN 
Zinc finger FYVE domain-containing protein 19  ZFY19_HUMAN 
Zinc finger protein 185  ZN185_HUMAN 
Zyxin  ZYX_HUMAN 
  Proteins identified by phospho-proteomic analysis whose phosphorylation 
levels do not significantly change after gefitinib treatment.  Phosphopeptides 
were matched to proteomic databases for protein identification using Scaffold 
software.  The amount of phosphorylation was compared between the DMSO 
vehicle control and gefitinib treated cells.   	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Supplemental Figure 2: 11510:pFR_HCV_xb Dual reporter luciferase plasmid map.  
 	   	  
The dual-reporter luciferase plasmid selectively measures cap-
dependent translation through Firefly luciferase and cap-independent 
translation through Renilla luciferase.  
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Supplemental Table 2: Mutational status of common genes.  
 
 
 BT20 MDA-MB-231 MDA-MB-468 
p53 mut mut mut 
BRCA wt wt wt 
PTEN wt wt loss 
PIK3CA mut wt wt 
Kras wt mut wt 
Hras wt wt wt 
Braf wt mut wt 
p16 del del wt 
p14ARF del del wt 
rb1 wt wt del 
chek2 wt wt wt 
myc wt wt wt 	  	  
Common genetic mutations and losses are described in the table arranged by TNBC 
cell type. mut indicates a mutation, del a deletion, and wt indicates the gene is wild type.  	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Supplemental Methods: 
Phospho- Proteomics Analysis 
BT20 cells were washed with ice cold HANK’s solution then proteins precipitated 
with 100% EtOH before cell proteins were scraped from plates and transferred to 
microcentrifuge tubes.  Proteins were solubilized in 0.2 ml of Tris, 10 mM pH=7.5, LiF, 1 
mM, Na3VO4, 0.1 mM, EDTA (Ethylenediaminetetraacetic acid) 1 mM and LiDS (Lithium 
Dodecyl Sulfate) 0.5%.  Non-soluble material was removed by filtration through Spin 
Columns (Pierce, Rockford, IL, USA) and protein content determined by BCA protein 
assay.  Samples were reduced with 10 mM dithiothreitol, alkylated with 30 mM 
iodoacetamide and 900 µg protein digested with 1:100 TPCK-treated trypsin (Sigma) 
after dilution to reduce LiDS concentration to 0.1% and addition of 10% acetonitrile.  
Samples were filtered through 0.45 µm 13 mm GHP filters (Pall, Port Washington, NY, 
USA) then phosphopeptides selected by incubation with 6 mg/sample TiO2 beads (GL 
Sciences, Torrance, CA, USA, 5 µm). 
The selectivity of the 6 mg of 5 µM TiO2 procedure for phosphopeptides was 
95%. Cell digests were incubated with TiO2 in 2% TFA (Trifluoroacetic acid) saturated 
with glutamic acid in 60% acetonitrile.  The beads were washed three times with 1% 
TFA in 60% acetonitrile before eluting phosphopeptides with NH4OH in 50% acetonitrile.  
TiO2 elutes were neutralized with formic acid, dried under vacuum and stored at -80°C 
until analysis. Eluted peptides solubilized in 0.1% formic acid were then analyzed by 
LC-MS/MS (Liquid chromatography–mass spectrometry) without further purification.   
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Mass Spectrometry:  All analyses were performed on a Thermo LTQ equipped with ETD 
(electron-disassociation transfer) (ThermoFisher Scientific, Watham, MA, USA). 
Samples were loaded on a peptide Captrap (Michrom, Auburn, CA, USA) trapping 
column and peptide separations achieved using a linear gradient of 5% to 35% 
acetonitrile to elute from a Majic 0.1 mm x 150 mm AQ C18 column (Michrom).  LC-
MS/MS was run in a neutral loss mode so that high abundance precursor neutral losses 
of 24.25, 32.66, or 49.00 m/z found in an MS2 spectrum were selected for MS3 
analysis.   
Database Searching:  Tandem mass spectra were extracted by Proteome 
Discoverer (ThermoFisher Scientific) version 1.4.0.288.  Charge state deconvolution 
and deisotoping were not performed. All MS/MS data were analyzed using Mascot 
(Matrix Science, London, UK; version 2.4.0) and X! Tandem (The GPM, thegpm.org; 
version CYCLONE (2010.12.01.1)). Mascot and X!Tandem were each set up to search 
the uniprot_sprot_20110405 database (selected for Homo sapiens, 20305 entries) 
assuming the digestion enzyme trypsin.  Spectra were searched with a fragment ion 
mass tolerance of 0.70 Da and a parent ion tolerance of 3.5 Da.  The iodoacetamide 
derivative of cysteine was specified as a fixed modification. Oxidation of methionine, 
acetylation of the N-terminus and phosphorylation of serine, threonine and tyrosine 
were specified as variable modifications.   
Criteria for Protein Identification:  Scaffold (version 4.0.5, Proteome Software 
Inc., Portland, OR, USA) was used to validate MS/MS based peptide and protein 
identifications. Peptide identifications were accepted if they could be established at 
greater than 95.0% probability by the Peptide Prophet algorithm.(Keller et al., 2002) 
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Protein identifications were accepted if they contained at least one identified 
phosphopeptide and had a Protein Prophet probability greater than 80%.(Nesvizhskii et 
al., 2003) Proteins that contained similar peptides and could not be differentiated based 
on MS/MS analysis alone were grouped to satisfy the principles of parsimony.  All 
subsequent analysis of protein sets included all proteins or peptides that met the criteria 
for identification without weighting for the level of confidence in the identification.   
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Triple negative breast cancer (TNBC) patients suffer from a highly malignant and 
aggressive cancer that lacks an effective targeted therapeutic. Although many TNBCs, 
both in vitro and in vivo, have increased expression of epidermal growth factor receptor 
(EGFR), EGFR targeted inhibitors, such as gefitinib (GEF), have yet to demonstrate 
efficacy. Using mass spectrometry to identify pathways that remain activated in the 
presence of GEF, we found that components of the mTOR signaling pathway remain 
phosphorylated. While inhibiting mTOR with temsirolimus (TEM) decreased mTOR 
signaling, EGFR signaling pathways remained activated and the TNBC cell lines 
continued to proliferate. However, dual treatment with TEM and GEF synergistically 
decreased cell viability in TNBC cells. Interestingly, abrogation of both EGFR and 
mTOR signaling did not alter the phosphorylation of key growth signaling molecules 
including MAPK and AKT. Instead, our data have identified the translational control 
pathway, specifically, eIF4B as a potentially key regulatory point in EGFR and mTOR 
inhibitor synergy. Further, we have also identified the transcription factor, STAT3 as 
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another regulatory point in the EGFR and mTOR inhibitor synergy. Therefore, in this 
study we hypothesized that mTOR inhibition can sensitize TNBC cells to EGFR TKIs 
through the inhibition of eIF4B and STAT3 phosphorylation.  
eIF4B enhances the helicase activity of eIF4A during translation initiation. As 
expected, knockdown of eIF4B expression decreased cell viability comparable to the 
decrease observed with the combination treatment. Importantly, we have identified 
p70S6K and p90RSK as kinases directly responsible for eIF4B phosphorylation, such 
that both molecules need to be inactivated in order for eIF4B phosphorylation to be 
abrogated. This inactivation correlated with a loss of cell growth and viability and a 
decrease in clonogenic cell survival, potentially through alterations in the cell cycle. 
Furthermore, cap-dependent translation was inhibited to a greater extent in the 
combination treatment than GEF or TEM alone. Taken together these data suggest that 
EGFR and mTOR inhibitor combination abrogates cell growth, viability, and survival via 
disruption of translational control mechanisms through eIF4B. 
STAT3 is a widely considered oncogenic transcription factor that has been 
implicated in a variety of cancer types. We found a decrease in phospho-STAT3 with 
the GEF+TEM combination. Further DNA binding ELISAs found STAT3 activity was 
also significantly decreased with the combination. Overexpression of a constitutively 
active STAT3 plasmid found that STAT3 activation negates the GEF+TEM synergetic 
effect on cell viability. Together, these studies suggest a role for STAT3 in EGFR and 
mTOR inhibitor synergy.  
Taken together these data suggest that in the presence of activated MAPK and 
AKT, EGFR and mTOR inhibitors abrogate growth, viability, and survival via disruption 
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of eIF4B and STAT3 phosphorylation leading to decreased translation and transcription 
factor DNA binding, respectively, in TNBC cell lines. The effect translation has on 
cancer cells in regard to the mTOR and EGFR pathways is largely unexplored in TNBC 
and further implicates eIF4B as a protein of interest in understanding the gefitinib and 
temsirolimus synergy. TNBC patients currently have limited treatment options and our 
data suggest that including an mTOR inhibitor along with an EGFR inhibitor in TNBC 
with increased EGFR expression should be further explored. 
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